

CURRICULUM VITAE

Eleftherios Mylonakis, M.D., Ph.D., FIDSA

Charles C.J. Carpenter Professor of Infectious Disease
Professor of Medicine and Professor of Molecular Microbiology and Immunology
Chief, Infectious Diseases Division
Assistant Dean for Outpatient Investigations
Director, COBRE Center for Antimicrobial Resistance and Therapeutic Discovery
Director, Center for Outpatient and Longitudinal Medical Research

Business Address: Rhode Island Hospital
Division of Infectious Diseases
593 Eddy Street
Physicians Office Building
3rd Floor, Suite 328/330
Providence, Rhode Island 02903

Business Telephone Number: (401) 444-7845

Business Fax Number: (401) 444-8179

Electronic Mail Address: emylonakis@lifespan.org

EDUCATION

1984-1990 M.D., National and Kapodistrian University of Athens, Greece

1990-1994 PH.D., National and Kapodistrian University of Athens, Greece

POSTGRADUATE TRAINING

Residency

10/91-09/92 Resident in Medicine, Kapodistrian National University, Evangelismos Hospital, Athens, Greece

09/92-10/93 Research Associate, National University of Athens and Evangelismos Hospital, Athens, Greece

10/93-06/95 Physician, Infectious Diseases and HIV Unit, Evangelismos Hospital, Athens, Greece

07/95-06/98 Intern, Junior Resident and Senior Resident in Internal Medicine, The Miriam Hospital, Brown University

07/98-06/99 Chief Resident in Medicine, The Miriam Hospital and Providence VA Medical Center, Brown University

Fellowship

- 07/99-08/01 Clinical and Research Fellow in Medicine, Infectious Disease Division, Massachusetts General Hospital and Brigham and Women's Hospital Combined Infectious Disease Fellowship, Boston, MA
- 08/01-08/02 Research Fellow in Medicine, Harvard Medical School, Boston, MA (laboratory of Dr. S.B. Calderwood)

POSTGRADUATE HONORS AND AWARDS

- 1993 Award in Chemotherapy Research, Amphiraion Foundation, National Medical Conference, Athens, Greece
- 1996 Voted "Intern of the Year", Providence VA Medical Center, Brown University, Providence, RI
- 1996 Voted "Most Valuable Resident", The Miriam Hospital, Brown University, Providence, RI
- 1999 "Teacher of the year," Voted by the Senior Medical students of the Brown University
- 2004 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Young Investigator Award, American Society for Microbiology
- 2005 Maxwell Finland Award for excellence in Infectious Disease Research, Massachusetts Infectious Disease Society
- 2010 The Oswald Avery Award, Infectious Disease Society of America (IDSA)
- 2011- American Society for Clinical Investigation, Member
- 2011 Partners in Excellence award in Leadership and Innovation
- 2013 Master of Arts (*Hon. Causa*), Brown University, Providence, RI
- 2014 17th annual Hygeia Award, The New England Hellenic Medical and Dental Society
- 2019 Doctor of Science (*Hon. Causa*), National and Kapodistrian University of Athens, Greece

MILITARY SERVICE

- 10/90-09/91 Intern in Medicine, First Department of Medicine, Army Hospital, Athens, Greece

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

- 1999 Diplomate, American Board of Internal Medicine (recertified 10/2019 and certificate valid through 2029)
- 2001 Diplomate, American Board of Internal Medicine, Subspecialty: Infectious Disease (certificate valid through 2021)
- 2002-2012 Massachusetts Registered Physician
- 2012- Rhode Island Registered Physician

ACADEMIC APPOINTMENTS

- 2002-2004 Instructor in Medicine, Medicine-Massachusetts General Hospital, Boston, MA
- 2005-2009 Assistant Professor of Medicine, Harvard Medical School
- 2009-2012 Associate Professor of Medicine, Harvard Medical School
- 2012- Director, Division of Infectious Diseases, Warren Alpert Medical School of Brown University
- 2012- Professor of Molecular Microbiology and Immunology, Warren Alpert Medical School of Brown University
- 2012-2017 Dean's Professor of Medical Science, Warren Alpert Medical School of Brown University
- 2012-2014 Visiting Professor, Harvard Medical School
- 2012-2016 Visiting Professor, Southern Medical University, Guangzhou, P.R. China
- 2017- Charles C.J. Carpenter Professor of Infectious Disease, Warren Alpert Medical School of Brown University
- 2018- Director, COBRE Center for Antimicrobial Resistance and Therapeutic Discovery
- 2019- Assistant Dean for Outpatient Investigations, Brown University
- 2019- Director, Center for Outpatient and Longitudinal Medical Research

HOSPITAL APPOINTMENTS

- 09/03-12/05 Clinical Assistant in Medicine, Massachusetts General Hospital, Boston, MA
- 01/06-5/09 Assistant in Medicine, Massachusetts General Hospital, Boston, MA
- 5/09-12/11 Assistant Physician, Massachusetts General Hospital, Boston, MA
- 12/11-6/12 Associate Physician, Massachusetts General Hospital, Boston, MA

- 9/09-6/12 Consultant in Infectious Disease, Massachusetts Eye and Ear Infirmary, Boston, MA
- 7/12- Staff Physician, Rhode Island Hospital and The Miriam Hospital
- 7/12- Director, Division of Infectious Diseases, Rhode Island Hospital and The Miriam Hospital
- 7/13-8/16 Consultant (Medicine Service), Massachusetts General Hospital, Boston, MA

Other appointments

- 2006 Scientific Advisory Committee, Annual Infectious Disease Update, National Research Centre, Athens, Greece
- 2007 Scientific Program Committee, Annual Infectious Disease Update, National Research Centre, Athens, Greece
- 2009 Member, Organizing Committee, Annual Infectious Disease Update, National Research Centre, Athens, Greece
- 2009- Founding editor and Editor-in-Chief, *Virulence*
- 2010 Organizer, 1st International Meeting on Model Hosts, Crete, Greece
- 2010 Scientific Advisory Board, HFP2011 Course on Human Fungal Pathogens: Molecular Mechanisms of Host-Pathogen Interactions and Virulence, La Colle sur Loup, France
- 2010 Member, Scientific Advisory Board, Fourth Lecture Course on Human Fungal Pathogens, Human Fungal Pathogens: Molecular Mechanisms of Host-Pathogen Interactions and Virulence May 7-13, 2011, La Colle sur Loup, France
- 2010-2011 Director, Hellenic Pasteur Institute
- 2012 Member, Scientific Advisory Board, Fourth Lecture Course on Human Fungal Pathogens, Human Fungal Pathogens: Molecular Mechanisms of Host-Pathogen Interactions and Virulence, 2013, La Colle sur Loup, France
- 2012 Co-chair, RI Department of Health Infectious Diseases & Epidemiology Advisory Committee
- 2012 Member, Scientific Advisory Board, Ocean State Angels Fund, LLC
- 2012 Member, Brown University Kenya Program
- 2012- ASCI representative for Brown University and Lifespan
- 2013-2016 Member, IDWeek Program Committee (IDWPC)
- 2013 Member, External Advisory Committee, Harvard Institutes of Medicine
- 2013 Member, Brown Review Committee, Translational Seed Grant Program

- 2015- Member, New England Comparative Effectiveness Public Advisory Council (CEPAC) <http://cepac.icer-review.org/>
- 2015 Member of the 5-person external committee that evaluated the Kapodistrian University of Athens, Greece for national and European Union accreditation.
- 2016- Member, International Advisory Board, Global Alliance for Infections in Surgery.
- 2016- Member, Consensus Document on the “Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective”, ESCMID (European Society of Clinical Microbiology and Infectious Diseases) Study Group for Infections in Compromised Hosts (ESGICH).
- 2016- BioMed Awards Committee, Brown University
- 2016- Undergraduate Teaching and Research Awards selection committee, Brown University
- 2018 *Journal of Fungi* Travel Award competition for PhD students and postdocs
- 2018 External evaluator of the LOEWE Center for Insect Biotechnology & Bioresources, Giessen, Germany.
- 2018- Chair, Selection Committee for the Position of Chief of Geriatrics Division, Alpert Medical School of Brown University and Rhode Island Hospital and The Miriam Hospital
- 2019 *Journal of Fungi* Travel Award competition for PhD students and postdocs

Grant Review Activities

- 2006 Ad-Hoc Reviewer, Medical Research Council (MRC), UK
- 2007 NSF advisory panel for the Symbiosis, Defense and Self-recognition (SDS) program in the Physiological and Structural Systems Cluster, Division of Integrative Organismal Systems, The National Science Foundation, Arlington, VA
- 2007 Ad-Hoc Reviewer ("Referee"), International Centre for Diarrhoeal Disease Research, Bangladesh
- 2008 Ad-Hoc Reviewer, National Science Foundation (NSF)
- 2008 Ad-Hoc Reviewer, Albert Einstein /MMC Center for AIDS Research (CFAR).
- 2009 Ad-Hoc Reviewer ("Referee"), NIH, Challenge Grants Panel 4
- 2009 Member, NIH-National Institute of Dental and Craniofacial Research (NIDCR), Member of the Scientific Review Group ZDE1 RK (28)

- 2009 Ad-Hoc Reviewer, UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)
- 2009 Ad-Hoc Reviewer, National Agency for Science, Technology and Research's and Biomedical Research Council (BMRC), Singapore
- 2010 Member, NIH-NIAID, Member of the Scientific Review Group ZAI1-LG-M-C4- *In Vitro* Assessments for Antimicrobial Activity-Toxins
- 2010 Member, NIH-NIAID, Member of the Scientific Review Group ZAI1-LG-M-C1- *In Vitro* Assessments for Antimicrobial Activity-Bacterial and Fungi
- 2010 Member, NIH-NIAID, Member of the Scientific Review Group ZRG1 IDM S-Member Conflict: Topics in Microbial Diseases (alternate chair)
- 2011 Ad-Hoc Reviewer, Research Fund for the Control of Infectious Disease (RFCID) and the Health and Health Services Research Fund (HHSRF), Hong Kong SAR Government
- 2013 Reviewer, Centers of Excellence for Translational Research, CETR, DHHS NIH NIAID
- 2013 Ad-Hoc Reviewer, CAREER award, Symbiosis Def & Self Recog, NSF
- 2014 Ad-Hoc Reviewer, Danish Council for Independent Research | Technology and Production Sciences
- 2016 Member, Study section: Topics in Infectious Diseases and Drug Discovery Meeting, NIAID
- 2016 Ad-Hoc Reviewer, "Immunology and Infection" Evaluation Committee of the French National Research Agency (ANR).
- 2016 Member, Study section: Topics in Biology of Infectious Diseases Agents, Drug Resistance and Drug Discovery, NIAID
- 2016 Member, Study section: Topics in Biology of Infectious Diseases Agents, Drug Resistance and Drug Discovery, NIAID
- 2017 Ad-Hoc Reviewer, German-Israeli Foundation for research (GIF)
- 2018 Ad-Hoc Reviewer, W. M. Keck Foundation
- 2018 Ad Hoc Reviewer, Austrian Federal Ministry of Education, Science and Research
- 2018 Member, Special Emphasis Panel (SEP) RFP-NIAID-DMID-NIHAI2017091, In Vitro Assessments of Antimicrobial Activity (IVAAA), NIAID
- 2018 Ad Hoc Reviewer, UK Space Agency Microgravity Experiments

2019 Health Research Board (HRB), Ireland

Editorial Roles

Year(s)	Role	Journal Name
2000-2004	Member, Editorial Board	The American Journal of Medicine and Sports
2006-	Member, Editorial Board	PLoS ONE
2005-	Member, Editorial Board	Research Journal of Microbiology
2007-	Member, Editorial Board	The Open Parasitology Journal
2007-2013	Member, Editorial Board	Eukaryotic Cell
2010	Member, Editorial Board	Journal of Drug Assessment
2010-2019	Editor-in-Chief	Virulence
2011	Guest Editor	Current Pharmaceutical Design
2011-	Member, Editorial Board	BioLetters
2011-	Member, Editorial Board	Medical Sciences
2013-	Member, Editorial Board	Journal Medical Sciences
2014-	Member, Editorial Board	Fungi
2015-	Member, Editorial Board	Advances in Microbiology, Infectious Diseases and Public Health.
2017-	Associate Editor	ACP Journal Club (ACPJC).

Ad-Hoc Reviewer: ACS Chemical Biology, ACS Inf Dis, AIDS and Public Policy Journal, AIDS Reader, American Family Physician, American Journal of Medicine and Sports, Antimicrobial Agents and Chemotherapy, Applied and Environmental Microbiology, Archives of Internal Medicine, Archives of Medical Research, Cancer Control: Journal of the Moffitt Cancer Center, Cell Host & Microbe, Circulation, Clinical Infectious Diseases, Current Genetics, Eukaryotic Cell, Experimental Parasitology, Expert Opinion in Pharmacotherapy, Expert Opinion on Drug Discovery, FEMS Yeast Research, FirstConsult, Hospital Physician, Geriatrics, Infection, Infection and Immunity, Infections in Medicine, JAMA: Journal of the American Medical Association, Journal of Clinical Microbiology, Journal of the American Society of Nephrology, Journal of Immunology, McMaster Online Rating of Evidence, Medical Mycology, Molecular Microbiology, Mycopathologia, PLoS Pathogens, Proc Natl Acad Sci USA, Recent Patents on Anti-Infective Drug Discovery, Southern Medical Journal, The Journal of Infectious Diseases, The Lancet, The New England Journal of Medicine, Transplant Infectious Disease, Transplantation, World Journal of Surgery

HOSPITAL COMMITTEES

2011-2012	Antifungal Stewardship Coordinator, Massachusetts General Hospital
2012-2018	Research Advisory Committee, RI Hospital
2012-2018	DoM Clinical Revenue Committee, University Medicine
2012-	Promotions Committee, Department of Medicine, Alpert Medical School of Brown University
2013-	Clinical Investigator/Research Residency Track Planning Committee, RI Hospital
2013-	Resident Selection Committee, Brown University

MEMBERSHIP IN SOCIETIES

1992-1996	Infectious Diseases Society of Greece, Member
1995-	American Society for Microbiology, Member
1997-2000	American Association for the Advancement of Science, Member
1997-2000	American College of Physicians, Member
2000-2006	Massachusetts Medical Society, Member
2000-2009	Infectious Diseases Society of America, Member
2009-	Fellow, Infectious Diseases Society of America
2011-	American Society for Clinical Investigation
2019-	Fellow, American Academy of Microbiology
2019-	Member, Association of American Physicians (AAP)

Publications

1. Mylonakis E, Chalevelakis G. [Infections by atypical mycobacteria]. *Nosocomiaka Chronika*. 55(3); 156-161; 1993.
2. Mylonakis E, Saroglou G. [Traveler's diarrhea]. *Iatriki* 68(2): 159-64; 1995.
3. Mylonakis E, Chalevelakis G. [Newer antifungal agents]. *Nosocomiaka Chronika*. 57(3): 185-90; 1995.
4. Mylonakis E, Rich J, Kwakwa H, Flanigan T, De Orchis D, Boyce J, Mileno MD. Muscle abscess due to *Aspergillus fumigatus* in an AIDS patient. *Clin Infect Dis*. 1996;23:1323-4.
5. Koutkia P, Mylonakis E, Flanigan T. Enterohemorrhagic *Escherichia coli* O157:H7 An emerging pathogen. *Am Fam Physician*. 1997;56:853-9.

6. Mylonakis E, Nizam R, Freeman N. Periurethral abscess: complication of UTI. *Geriatrics*. 1997;52:86-9.
7. Mylonakis E, Chalevelakis G, Saroglou G, Danias P, Argyropoulou A, Paniara O, Raptis S. Efficacy of desoxycholate amphotericin B and unilamellar liposomal amphotericin B in prophylaxis of experimental *Aspergillus fumigatus* endocarditis. *Mayo Clin Proc*. 1997;72:1022-7.
8. Mylonakis E, Rich J, Skolnik P, De Orchis D, Flanigan T. Invasive *Aspergillus* sinusitis in patients with human immunodeficiency virus infection. *Medicine [Baltimore]*. 1997;76:249-5.
9. Mylonakis E, Flanigan T. Anti-fungal prophylaxis with weekly fluconazole for patients with AIDS [editorial]. *Clin Infect Dis*. 1998;27:1376-8.
10. Mylonakis E, Rich JD. Laboratory diagnosis of cytomegalovirus infection in HIV-infected patients. *Infectious Disease Practice*. 1998;22:88-9.
11. Mylonakis E, Rich JD. Laboratory diagnosis of toxoplasmosis in HIV-infected patients. *Infectious Disease Practice*. 1998;22:99.
12. Mylonakis E, Rich JD. Management of toxoplasmosis in HIV-infected patients. *Antibiotics for Clinicians*. *Antibiotics for Clinicians*. 1998;2(5):106.
13. Mylonakis E, Rich JD. Update on the management of AIDS-related cytomegalovirus retinitis. *Antibiotics for Clinicians*. 1998;2(5):86-7.
14. Danias P, Chalevelakis G, Mylonakis E, Saroglou G, Argyropoulou A, Paniara O, Raptis S. Comparative in vitro and in vivo efficacy of roxithromycin and erythromycin against a strain of methicillin-susceptible *Staphylococcus epidermidis*. *Diagn Microb Infect Dis*. 1998;32:51-4.
15. Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with *Listeria monocytogenes*: 33 years' experience at a general hospital and review of 776 episodes from the literature. *Medicine [Baltimore]*. 1998;77:313-36.
16. Mylonakis E, Barlam TF, Flanigan T, Rich J. Pulmonary aspergillosis in the acquired immunodeficiency syndrome: review of 342 cases. *Chest*. 1998; 114:251-62.
17. Mylonakis E, Mileno MD, Flanigan T, De Orchis D, Rich J. Pulmonary invasive aspergillosis in HIV-infected patients. Report of two cases. *Heart Lung*. 1998;27:63-6.
18. Mylonakis E, Koutkia P, Dickinson BP, Rich J, Flanigan T, Horwitz H. Vasculitis and HIV. *AIDS Reader*. 1998;8:192-3.
19. Koutkia P, Mylonakis E, Flanigan T. Cookouts and seasonal peak of *Escherichia coli* infection [letter]. *Am Fam Physician*. 1998;57:1494.
20. Mylonakis E, Koutkia P, Rich JD, Tashima KT, Fiore TC, Flanigan T, Carpenter CCJ. Substance abuse is responsible for most pre-AIDS deaths among women with HIV infection in Providence, RI, USA [letter]. *AIDS*. 1998;12:958-9.
21. Mylonakis E, Dickinson BP, Feller A, Sweeney J, Schiffman FJ, Rich J, Flanigan T. Combination antiretroviral therapy including a protease inhibitor decreased the transfusion

- requirements of HIV-infected individuals with anemia of chronic disease [letter]. *J Acquir Immune Defic Syndr Hum Retrovirology*. 1998;19:306-7.
22. Dickinson BP, Mitty JA, Mylonakis E, Rich JD, Merriman NA, Tashima KT, Carpenter CCJ, Flanigan TP. Predictors of undetectable HIV plasma viral loads in 250 HIV-positive women receiving care [letter]. *AIDS*. 1998;12:2075-6.
 23. Dickinson BP, Mylonakis E, Strong LL, Rich JD. Potential infections related to anabolic steroid injection in young adolescents [letter]. *Pediatrics* 1999;103:694.
 24. Rich JD, Mylonakis E, Flanigan TP. Misdiagnosis of HIV-1 infection [letter]. *Ann Intern Med*. 1999;131:547-8.
 25. Mylonakis E. Do-not-resuscitate orders in radiology departments [letter]. Letter. *Ann Intern Med*. 1999;131:72-3.
 26. Mylonakis E, Koutkia P. Research during residency [letter]. *JAMA*. 1999;281:2088.
 27. Mylonakis E, Merriman NA, Rich JD, Walters BC, Tashima K, Mileno MD, van der Horst CM. Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis. *Diagn Microb Infect Dis*. 1999;34:111-4.
 28. Grumbach N, Mylonakis E, Wing EJ. Development of *Listeria* meningitis during ciprofloxacin therapy. *Clin Infect Dis*. 1999;29:1340-1.
 29. Chodock R, Mylonakis E, Shemin D, Runasdottir V, Yodice P, Renzi R, Towe C, Rich JD. Nucleoside associated lactic acidosis: Review and case report of survival with hemodialysis. *Nephrol Dial Transpl*. 1999;14:2484-6.
 30. Chang A, Mylonakis E, Karanasias P, De Orchis D, Gold R. Spontaneous bilateral vertebral artery dissection. Case report and review. *Mayo Clin Proc*. 1999;74:893-6.
 31. Rich JD, Dickinson BP, Flaxman AB, Mylonakis E. Local spread of molluscum contagiosum by electrolysis. *Clin Infect Dis*. 1999;28:1171.
 32. Mylonakis E, Kon D, Moulton A, Elion J, Indeglia R, Koutkia P, Katz A. Thrombosis of mitral valve prosthesis presenting as abdominal pain. *Heart Lung*. 1999;28:110-3.
 33. Mylonakis E, Dickinson BP, Mileno MD, Flanigan TP, Schiffman FJ, Mega A, Rich JD. Persistent parvovirus B19-related anemia of seven years duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy. *Am J Hematol*. 1999;60:164-6.
 34. Rich JD, Mylonakis E, Nossa R, Chapnick RM. Highly active antiretroviral therapy-associated resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. *Dig Dis Sci*. 1999;44:1034-7.
 35. Mylonakis E, Vittorio CC, Hollik D, Rounds S. Lamotrigine toxicity presenting as anticonvulsant hypersensitivity syndrome. *Ann Pharmacother*. 1999;33:557-9.
 36. Rich JD, Dickinson BP, Feller A, Pugatch D, Mylonakis E. Infectious complications of anabolic steroids. *Int J Sports Med*. 1999;20:563-6.
 37. Koutkia P, Mylonakis E, Boyce J. Cellulitis: Evaluation of possible predisposing factors in hospitalized patients. *Diagn Microb Infect Dis*. 1999;34:325-7.

38. Mylonakis E, Mega A, Schiffman FJ. What do program directors in internal medicine think about international medical graduates? Results of a pilot study. *Acad Med.* 1999;74:452.
39. Rich JD, Merriman NA, Mylonakis E, Greenough TC, Flanigan TP, Mady BJ, Carpenter CCJ. The emergence of false positive HIV-1 plasma viral loads: a case series. *Ann Intern Med.* 1999;130:37-9.
40. Mylonakis E, Paliou M, Greenbough TC, Flanigan T, Letvin N, Rich J. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV status. *Arch Intern Med.* 2000;160:2386-8.
41. Mylonakis E, Paliou M, Sax PE, Skolnik PR, Baron MJ, Rich JD. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. *Medicine [Baltimore].* 2000;79:269-80.
42. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. Laboratory testing for infection with the human immunodeficiency virus (HIV): established and novel approaches. *Am J Med.* 2000;109:568-76.
43. Mylonakis E, Feller AA, Salas CM, Rich JD. Infectious and non-infectious complications of anabolic steroids in adults and adolescents. *Am J Med Sports.* 2000;2:250-5.
44. Mylonakis E, Akhtar MS, Lopez F, Hussain I, Chen JL, Koutkia P, Lamberton P, Schiffman FJ. Resolution of methimazole-induced agranulocytosis with human granulocyte colony stimulating factor (G-CSF). *Geriatrics.* 2000;55:89-91.
45. Lopez FF, Mangi A, Mylonakis E, Chen JL, Schiffman FJ. Atrial fibrillation and tumor emboli as manifestations of metastatic leiomyosarcoma to the heart and lung. *Heart Lung.* 2000;29:47-9.
46. Mylonakis E. What is babesiosis? (patient handout) *Am Fam Phys* 2001;63:1975.
47. Filbin MR, Mylonakis EE, Callegari L, Legome E. Babesiosis. *J Emerg Med.* 2001;20:21-4.
48. Koutkia P, Mylonakis E, Erickson A, Rounds S. Cutaneous leukocytoclastic vasculitis associated with oxacillin therapy. *Diagn Microb Infect Dis.* 2001;39:191-4.
49. Mylonakis E. When to suspect and how to monitor babesiosis. *Am Fam Phys.* 2001;63:1969-74.
50. Mylonakis E, Koutkia P, Grinspoon S. Diagnosis and treatment of androgen deficiency in HIV-infected men and women. *Clin Infect Dis.* 2001;33:857-64.
51. Mylonakis E, Goes N, Rubin RH, Cosimi AB, Colvin RB, Fishman JA. BK virus in solid organ transplant recipients: an emerging syndrome. *Transplantation.* 2001;72:1587-92.
52. Mylonakis E, Ryan ET, Calderwood SB. *Clostridium difficile*-associated diarrhea. A review. *Arch Intern Med.* 2001;161:525-33.
53. Koutkia P, Mylonakis E, Erickson A, Rounds S. Leukocytoclastic vasculitis: an update for the clinician. *Scand J Rheumatol.* 2001;30:315-22.
54. Mylonakis E, Paliou M, Rich JD. Plasma viral load testing in the management of HIV infection. *Am Fam Phys.* 2001;63:483-90.

55. Mylonakis E, Calderwood SB. Infective endocarditis in adults. *N Engl J Med*. 2001;345:1318-30.
56. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, Murray BE, Calderwood SB, Ausubel FM. A simple model host for identifying gram-positive virulence factors. *Proc Natl Acad Sci USA*. 2001;98:10892-7.
57. Mylonakis E, Ausubel FM, Perfect JR, Heitman J, Calderwood SB. Killing of *Caenorhabditis elegans* by *Cryptococcus neoformans* as a model of yeast pathogenesis. *Proc Natl Acad Sci USA*. 2002;99:15675-80. PMID: 12438649 PMCID: PMC137775
58. Mylonakis E, Paliou M, Hohmann E, Calderwood SB, Wing EJ, Listeriosis during pregnancy: a case series and review of 222 cases. *Medicine [Baltimore]*. 2002;81:260-9.
59. Mylonakis E, Kallas WM, Fishman JA. Treatment of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients using combination antiviral therapy. *Clin Infect Dis*. 2002;34:1337-41.
60. Mylonakis E*, Engelbert M*, Qin X, Sifri CD, Murray BE, Ausubel FM, Gilmore MS, Calderwood SB. *Enterococcus faecalis* *fsrB* gene, a key component of the *fsr* quorum sensing system, is associated with virulence in the rabbit endophthalmitis model. *combined first authorship. *Infect Immun*. 2002;70:4678-81.
61. Sifri CD, Mylonakis E, Singh KV, Qin X, Garsin DA, Murray BE, Ausubel FM, Calderwood SB. Virulence effect of *Enterococcus faecalis* protease genes and the quorum-sensing locus *fsr* in *Caenorhabditis elegans* and mice. *Infect Immun*. 2002;70:5647-50.
62. Feler A, Mylonakis E, Rich JD. Medical complications of anabolic steroids. *Med Health RI*. 2002;85:338-40.
63. Marty F, Mylonakis E. Use of antifungals in HIV infection. *Expert Opin Pharmacother*. 2003;3:91-102.
64. Mylonakis E, Ausubel FM, Tang RJ, Calderwood SB. The art of serendipity: killing of *Caenorhabditis elegans* by human pathogens as a model of bacterial and fungal pathogenesis. *Expert Rev Anti-infect Ther*. 2003;1:89-95.
65. Engelbert M*, Mylonakis E*, Ausubel FM, Calderwood SB, Gilmore MS. Contribution of gelatinase, serine protease and *fsr* to the pathogenesis of *Enterococcus faecalis* endophthalmitis. *combined first authorship. *Infect Immun*. 2004;72:3628-33.
66. Apidianakis Y, Rahme LG, Heitman J, Ausubel FM, Calderwood SB, Mylonakis E. Challenge of *Drosophila melanogaster* with *Cryptococcus neoformans* and the role of the innate immune response. *Eukaryot Cell*. 2004;3:413-9. PMID: 15075271 PMCID: PMC387633
67. Bhabhra R, Miley M, Mylonakis E, Boettner D, Fortwendel J, Panepinto JC, Postow M, Rhodes JC, Askew DS. Disruption of the *Aspergillus fumigatus* gene encoding the nucleolar protein CgrA impairs thermotolerant growth and reduces virulence. *Infect Immun*. 2004;72:4731-40.
68. Mylonakis E, Idnurm A, Moreno R, El Khoury J, Rottman JB, Ausubel FM, Heitman J, Calderwood SB. *Cryptococcus neoformans* Kin1 protein kinase homolog, identified

- through a *C. elegans* screen, promotes virulence in mammals. *Mol Microbiol.* 2004;54:407-19.
69. Moy T, Mylonakis E, Calderwood SB, Ausubel FM. Cytotoxicity from hydrogen peroxide produced by *Enterococcus faecium*. *Infect Immun.* 2004;72:4512-20.
 70. Mylonakis E, Moreno R, El Khoury J, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. *Galleria mellonella* as a model system to study *Cryptococcus neoformans* pathogenesis. *Infect Immun.* 2005;73:3842-50. PMID: 15972469 PMCID:PMC1168598
 71. Nielsen K, Cox GM, Litvintseva AP, Mylonakis E, Malliaris SD, Benjamin DK Jr., Giles SS, Mitchell TG, Casadevall A, Perfect JR, Heitman J. *Cryptococcus neoformans* alpha strains preferentially disseminate to the central nervous system during infection. *Infect Immun.* 2005;73:4922-33.
 72. Tang RJ, Breger J, Idnurm A, Gerik K, Lodge JK, Heitman J, Calderwood SB, Mylonakis E. *Cryptococcus neoformans* gene involved in mammalian pathogenesis identified by a *C. elegans* progeny-based approach. *Infect Immun.* 2005;73:8219-25.
 73. Mylonakis E, Aballay A. Worms and flies as genetically tractable animal models to study host-pathogen interactions. *Infect Immun.* 2005;73:3833-41.
 74. Fuchs BB, Mylonakis E. Using non-mammalian hosts to study fungal virulence and host defense. *Curr Opin Microbiol.* 2006;9:346-51.
 75. London R, Orozco B, Mylonakis E. The pursuit of cryptococcal pathogenesis: Heterologous hosts and the study of cryptococcal host/pathogen interactions. *FEMS Yeast Res.* 2006;6:567-73.
 76. Aperis G, Myriounis N, Spanakis E, Mylonakis E. Developments in the treatment of candidiasis: More choices, new challenges. *Expert Opin Investig Drugs.* 2006;15:1319-36.
 77. Spanakis E, Aperis G, Mylonakis E. New agents for the treatment of fungal infections: Clinical efficacy and gaps in coverage. *Clin Infect Dis.* 2006;43:1060-8.
 78. Aperis G, Mylonakis E. New triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. *Expert Opin Investig Drugs.* 2006;15:579-602.
 79. Wills-Petzold E, Himmelreich U, Mylonakis E, Rude T, Toffaletti D, Cox GM, Miller JL, Perfect JR. The characterization and regulation of the trehalose pathway and its importance in the pathogenicity of *Cryptococcus neoformans*. *Infect Immun.* 2006;74:5877-87.
 80. Mylonakis E. Who killed the worm and other fungal pathogenesis insights. *Microbe* 2007;2:600-6.
 81. Mylonakis E. Book Review: Management of infective endocarditis in the era of intravascular devices. *Clin Infect Dis* 2007;45(10):1405.
 82. Reese AJ, Yoneda A, Breger JA, Beauvais A, Liu H, Griffith CL, Bose I, Kim M-J, Skau C, Yang S, Sefko JA, Osumi M, Latge J-P, Mylonakis E, Doering TL. Loss of cell wall alpha-1,3-glucan affects *Cryptococcus neoformans* from ultrastructure to virulence. *Mol Microbiol.* 2007;63:1385-98.
 83. Maadani A., Fox KA, Mylonakis E, Garsin DA. *Enterococcus faecalis* mutations affecting virulence in the *C. elegans* model host. *Infect Immun.* 2007;75:2634-7.

84. Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E. *Galleria mellonella* as a model host to study infection by the *Francisella tularensis* live vaccine strain. *Microbes Infect.* 2007;9:729-34.
85. Fuchs BB, Tang RJ, Mylonakis E. The temperature-sensitive role of *Cryptococcus neoformans* ROM2 in cell morphogenesis. *PLoS ONE.* 2007;2:e368.
86. Fan W, Idnurm A, Breger J, Mylonakis E, Heitman J. Ecal, a sarco/Endoplasmic reticulum Ca²⁺-ATPase, is involved in stress tolerance and virulence in *Cryptococcus neoformans*. *Infect Immun.* 2007;75:3394-405.
87. Breger J, Fuchs BB, Aperis G, Moy T, Ausubel FM, Mylonakis E. Antifungal chemical compounds identified using a *C. elegans* pathogenicity assay. *PLoS Pathog.* 2007;3:e18. PMID: 17274686 PMCID: PMC1790726
88. Fuchs BB, Tegos GP, Hamblin MR, Mylonakis E. Susceptibility of *Cryptococcus neoformans* to photodynamic inactivation is associated with cell wall integrity. *Antimicrob Agents Chemother.* 2007;51:2929-36. PMID: 17548495 PMCID:PMC1932496
89. Kwon DS, Mylonakis E. Posaconazole: A new broad-spectrum antifungal agent. *Expert Opin Pharmacother.* 2007;8:1167-78.
90. Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. *PLoS Pathog.* 2007;3:e101.
91. Thakur JK, Arthanari H, Yang F, Pan S-J, Fan X, Breger J, Frueh DP, Gulshan K, Li D, Mylonakis E, Struhl K, Moye-Rowley WS, Cormack BP, Wagner G, Näär AM. A nuclear receptor-like pathway regulating multidrug resistance in fungi. *Nature* 2008;452:604-9.
92. Peleg A, Tampakakis E, Fuchs BB, Eliopoulos G, Moellering RC Jr, Mylonakis E. Prokaryote-eukaryote interactions identified using *Caenorhabditis elegans*. *Proc Natl Acad Sci USA.* 2008;105:14585-90. PMID: 18794525 PMCID: PMC2567192
93. Pukkila-Worley R., Mylonakis E. Epidemiology and management of cryptococcal meningitis: developments and challenges. *Expert Opin Pharmacother.* 2008;9:551-60.
94. Tampakakis E, Okoli I, Mylonakis E. A *C. elegans*-based, whole animal, in vivo screen for the identification of antifungal compounds. *Nat Protoc.* 2008;3:1925-31. PMID: 19180076
95. Karsaliakos P, Romanou V, Mylonakis E. [Developments in antifungal therapy]. *Iatrika Analecta.* 2008;2:588-590.
96. Karsaliakos P, Romanou V, Mylonakis E, Saroglou G. [Principles of travel medicine]. *Iatrika Analecta.* 2008;2:599-602.
97. Mylonakis E. *Galleria mellonella* and the study of fungal pathogenesis: Making the case for another genetically tractable model host [editorial]. *Mycopathologia* 2008;165:1-3.
98. Coleman JJ, Mylonakis E. The tangled web of signaling in innate immunity [editorial]. *Cell Host Microbe.* 2009;5(4):313-5.
99. Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr., Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in *Staphylococcus aureus*. *J Infect Dis.* 2009;199(4):532-6.

100. Cowen LE, Singh SD, Köhler JR, Collins C, Zaas AK, Schell W, Aziz H, Mylonakis E, Perfect JR, Whitesel L, Lindquist S. Harnessing Hsp90 function as a novel therapeutic strategy for fungal infectious disease. *Proc Natl Acad Sci USA*. 2009;106:2818-23.
101. Means TK, Mylonakis E, Tampakakis E, Puckett L, Stewart CR, Pukkila-Worley R, Hickman SE, Moore KJ, Calderwood SB, Hachohen N, Luster AD, El-Khoury J. Evolutionary-conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. *J Exp Med*. 2009;206(3):637-53. PMID: 19237602 PMCID:PMC2699123
102. Ziakas P, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. *Haematologica* 2009;94(7):998-1005.
103. Tampakakis E, Peleg A, Mylonakis E. The interaction of *Candida albicans* with an intestinal pathogen; *Salmonella enterica* serovar Typhimurium. *Eukaryot Cell* 2009;8:732-7. PMID: 19329669 PMCID: PMC2681611
104. Peleg A, Jara S, Monga D, Eliopoulos G, Moellering RC Jr, Mylonakis E. *Galleria mellonella* as a model system to study *Acinetobacter baumannii* pathogenesis and therapeutics *Antimicrob Agents Chemother*. 2009;53:2605-9.
105. Ziakas P, Mylonakis E. 4-months of rifampin compared to 9-months of isoniazid for the management of latent tuberculosis: A meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. *Clin Infect Dis*. 2009;49(10):1557-64.
106. Ngamskulrungrroj P, Himmelreich U, Breger J, Wilson C, Chayakulkeeree M, Krockenberger MB, Malik R, Daniel HM, Toffaletti D, Djordjevic JT, Mylonakis E, Meyer W, Perfect JR. The trehalose synthesis pathway: an integral part for the virulence composite for *Cryptococcus gattii*. *Infect Immun*. 2009;77(10):4584-96.
107. Okoli I, Coleman J, Tampakakis E, An F, Holson E, Wagner F, Conery AL, Larkins-Ford J, Wu G, Stern A, Ausubel FM, Mylonakis E. Identification of antifungal compounds active against *Candida albicans* using an improved high-throughput *Caenorhabditis elegans* assay. *PLoS ONE* 2009;4:e7025. PMID: 19750012 PMCID: PMC2737148
108. Pukkila-Worley R, Peleg AY, Tampakakis E, Mylonakis E. *Candida albicans* hyphal formation and virulence assessed using a *Caenorhabditis elegans* infection model *Eukaryot Cell* 2009;8(11):1750-8. PMID: 19557154 PMCID:PMC2695561
109. Peleg AY, LaSalvia MT, Mylonakis E, Silveira FP. Current approaches to prophylaxis against pulmonary viral and fungal infections in solid organ transplant recipients. *Curr Infect Dis Rep* 2009;11:209-15.
110. Coleman J, Mylonakis E. Efflux in fungi: la pièce de résistance. *PLoS Pathog*. 2009;5(6):e1000486. PMID: 19557154 PMCID:PMC2695561
111. Pukkila-Worley R, Holson E, Wagner F, Mylonakis E. Antifungal drug discovery through the study of invertebrate model hosts. *Curr Med Chem*. 2009;16(13):1588-95.
112. Carneiro H, Mylonakis E. Google Trends: A web-based tool for real-time surveillance of disease outbreaks. *Clin Infect Dis*. 2009;49(10):1557-64.

113. Fuchs BB, Mylonakis E. Our paths might cross: The role of the fungal cell wall integrity pathway in stress response and cross-talk with other stress response pathways. *Eukaryot Cell* 2009;8(11):1616-25.
114. Mylonakis E, Riedman EM. Virulence: A new multi-disciplinary journal [editorial]. *Virulence*. 2010;1:1.
115. Pukkila-Worley R, Mylonakis E. From the outside in and the inside out: Antifungal immune responses in *Caenorhabditis elegans*. *Virulence* 2010;1(3):111-2.
116. Muhammed M, Coleman JJ, Kourkoumpetis TK, Mylonakis E. Invertebrate animal models as tools to study fungal pathogenesis and treatment. *Journal of Invasive Fungal Infections* 2010;4:127-132.
117. Peleg A, Hogan D, Mylonakis E. Medically important bacterial-fungal interactions. *Nat Rev Microbiol* 2010;8:340-349.
118. Dai T, Tegos G, Zhiyentayev T, Mylonakis E, Hamblin MR. Photodynamic therapy for methicillin-resistant *Staphylococcus aureus* infection in a mouse skin abrasion model. *Laser Surg Med* 2010;42:38-44.
119. Coleman J, Okoli I, Tegos GT, Holson EB, Wagner FF, Hamblin MR, Mylonakis E. Characterization of plant-derived saponin natural products against *Candida albicans*. *ACS Chem Biol*. 2010;5:321-32. PMID: 20099897
120. Fuchs BB, Eby J, Nobile CJ, El Khoury JB, Mitchell AP, Mylonakis E. Role of filamentation in *Galleria mellonella* killing by *Candida albicans*. *Microbes Infect*. 2010;12:488-96.
121. Manolakaki D, Velmahos G, Kourkoumpetis T, Chang Y, Alam HB, De Moya MM, Mylonakis E. Candida infection and colonization among trauma patients. *Virulence*. 2010;1:367-75. PMID:21178472
122. Spanakis E, Kourkoumpetis T, Peleg A, Mylonakis E. Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. *Mayo Clin Proc*. 2010;85:1073-1079. PMID:21123633
123. Ziakas PD, Kourbeti IS, Voulgarelis M, Mylonakis E. Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: A meta-analysis of randomized controlled trials. *Clin Ther*. 2010;32:2316-2332.
124. Kourkoumpetis T, Manolakaki D, Velmahos G, Chang Y, Alam HB, De Moya MM, Sailhamer EA, Mylonakis E. Candida infection and colonization among non-trauma emergency surgery patients. *Virulence*. 2010;1(5):359-66. PMID:21178471
125. Carneiro H, Coleman J, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: A case series and literature review. *Medicine [Baltimore]*. 2011;90:69-80. PMID:21200188
126. Kourkoumpetis TK, Velmahos GC, Ziakas PD, Tampakakis E, Manolakaki D, Coleman JJ, Mylonakis E. The effect of cumulative length of hospital stay on the antifungal resistance of *Candida* strains isolated from critically ill surgical patients. *Mycopathologia*. 2011;171:85-91. PMID:20927595

127. Fuchs BB, Bishop LR, Kovacs JA, Mylonakis E. *Galleria mellonella* are resistant to *Pneumocystis murina* infection. *Mycopathologia*. 2011;171(4):273-7. PMID: 20922567
128. Campbell J, Singh AK, Santa Maria JP, Kim Y, Brown S, Swoboda JG, Mylonakis E, Wilkinson BJ, Walker S. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chem Biol*. 2011;6:106-16. PMID:20961110
129. Kim Y, Mylonakis E. Killing of *Candida albicans* filaments by *Salmonella enterica* serovar Typhimurium is mediated by the *sopB* effectors, parts of a type III secretion system. *Eukaryot Cell* 2011;10:782-90. PMID: 21498643
130. Pukkila-Worley R, Ausubel FM*, Mylonakis E*. *C. albicans* infection of *Caenorhabditis elegans* induces antifungal immune defenses. *PLoS Pathogens* 2011;7:e1002074. PMID: 21731485
131. Cohen NR, Tatituri RVV, Rivera A, Kim EY, Zhao Y, Fuchs B, Mylonakis E Gerald Watts GFM, Chiba A, Besra GS, Levitz SM, Brigl M, Brenner MB. Innate recognition of cell wall β -glucans via Dectin-1 drives iNKT cell responses against fungi. *Cell Host Microbe*. 2011;10(5):437-50. PMID: 22100160
132. Coleman JJ, Ghosh S, Okoli I, Mylonakis E. Antifungal activity of microbial secondary metabolites. *PLoS ONE* 2011;6(9):e25321. PMID: 21966496
133. Coleman JJ, Muhammed M, Kasperkovitz PV, Vyas JM, Mylonakis E. *Fusarium* pathogenesis investigated using *Galleria mellonella* as a heterologous host. *Fungal Biol*. 2011;115(12):1279-89. PMID: 22115447
134. Junqueira JC, Fuchs BB, Muhammed M, Coleman JJ, Suleiman J, Vilela SF, Costa A, Rasteiro V, Jorge A, Mylonakis E. Oral *Candida* isolates from HIV-positive *Candida* isolates. *BMC Microbiology* 2011 Nov 4;11:247. PMID: 22053894
135. Coleman JJ, Muhammed M, Kasperkovitz PV, Vyas JM, Mylonakis E. *Fusarium* pathogenesis investigated using *Galleria mellonella* as a heterologous host. *Fungal Biology* 2011 Dec;115(12):1279-89. PMID: 22115447
136. Fuchs BB, O'Brien E, Khoury JB, Mylonakis E. Methods for using *Galleria mellonella* as a model host to study fungal pathogenesis. *Virulence*. 2011;1(6):475-82.
137. Shenoy E, Mylonakis E, Hurtado R, Venna N. Natalizumab and HSV meningitis. *J Neurovirol*. 2011;17(3):288-90.
138. Carneiro H, Mylonakis E. *Candida* peritonitis: An update on the latest research and treatments. *World J Surgery* 2011;35(12):2650-9.
139. Desalermos A, Muhammed M, Glavis-Bloom J, Mylonakis E. Using *C. elegans* for antimicrobial drug discovery. *Expert Opin Drug Discov*. 2011;6:645-652. PMID: 21686092
140. Anastassopoulou CG, Fuchs BB, Mylonakis E. *Caenorhabditis elegans*-based model systems for antifungal drug discovery. *Curr Pharm Des*. 2011;17(13):1225-33.
141. Muhammed M, Carneiro H, Coleman J, Mylonakis E. The challenge of managing fusariosis. *Virulence*. 2011;1;2(2):91-6.

142. Riederer EM, Sharpe S, Mylonakis E. *Virulence*: The first two years. [editorial]. *Virulence* 2011;2(6):491-2.
143. Mylonakis E. The need to redefine antimicrobial drug discovery. *Curr Pharm Des*. 2011 PMID: 21470109
144. Mylonakis E, Muse VV, Mino-Kenudson M. A 74-year-old man with pemphigus vulgaris and lung nodules. *N Engl J Med* 2011;365(11):1043-50.
145. Desalermos A, Kourkoumpetis T, Mylonakis E. Update on the epidemiology and management of cryptococcal meningitis. *Expert Opin Pharmacother*. 2012;13(6):783-9.
146. Desalermos A, Fuchs B, Mylonakis E. Selecting an invertebrate model host for the study of fungal pathogenesis. *PLoS Pathogens* 2012;8(2):e1002451.
147. Glavis-Bloom J, Muhammed M, Mylonakis E. Of Model Hosts and Man: Using *Caenorhabditis elegans*, *Drosophila melanogaster* and *Galleria mellonella* as model hosts for infectious disease research. *Adv Exp Med Biol*. 2012;710:11-7.
148. Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St. Denis TG, Ribeiro MS, Mylonakis E, Hamblin MR, Tegos GP. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. *Front Microbiol*. 2012;3:120.
149. Kourkoumpetis T, Fuchs B, Coleman JJ, Desalermos A, Mylonakis E. PCR-based assays for the diagnosis of invasive fungal infections. *Clin Infect Dis*. 2012;54(9):1322-31.
150. Kourkoumpetis T, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from literature. *Medicine [Baltimore]*. 2012;91(6):328-36. PMID: 23117848
151. Oh S, Go GW, Mylonakis E, Kim Y. The bacterial signalling molecule indole attenuates the virulence of the fungal pathogen *Candida albicans*. *J Appl Microbiol*. 2012;113(3):622-8. PMID: 22726313
152. Suzuki T, Campbell J, Kim Y, Swoboda JG, Mylonakis E, Walker S, Gilmore MS. Wall teichoic acid protects *Staphylococcus aureus* from inhibition by Congo red and other dyes. *ACS Chem Biol*. 2011;6:106-16. *J Antimicrob Chemother*. 2012;67(9):2143-51. PMID: 22615298
153. Uppuluri P, Chaturvedi AK, Jani N, Pukkila-Worley R, Monteagudo C, Mylonakis E, Köhler JR, Lopez Ribot JL. Physiologic expression of the *Candida albicans* pescadillo homolog is required for virulence in a murine model of hematogenously disseminated candidiasis. *Eukaryot Cell*. 2012;11(12):1552-6. PMID: 23104566
154. Riedmann EM, Mylonakis E. *Virulence*: Three years and counting. *Virulence*. 2012;3(7). PMID: 23275253 PMCID: PMC3545930
155. Muhammed M, Coleman JJ, Fuchs BB, Mylonakis E. The role of mycelium production and a MAPK-mediated immune response in the *C. elegans-Fusarium* model system. *Med Mycol* 2012 Jul;50(5):488-96. PMID: 22225407
156. Cunha CB, Varughese CA, Mylonakis E. Antimicrobial stewardship programs (ASPs): The devil is in the details. *Virulence*. 2013;15:4(2):147-9. PMID: 23381468 PMCID: PMC3654613

157. Chiebebe Junior J, Fuchs BB, Sabino CP, Junqueira JC, Jorge AO, Ribeiro MS, Gilmore MS, Rice LOB, Tegos GP, Hamblin MR, Mylonakis E. Photodynamic and antibiotic therapy impair the pathogenesis of *Enterococcus faecium* in a whole animal insect model. PLoS ONE. 2013;8(2):e55926. PMID: 2345486
158. Omer AK, Ziakas PD, Anagnostou T, Coughlin E, Kourkoumpetis T, McAfee SL, Dey BR, Chen YB, Spitzer TR, Mylonakis E, Ballen KK. Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: A single center experience. Biol Blood Marrow Transplant 2013;19(8):1190-6. PMID: 23747459
159. Prates RA, Fuchs BB, Mizuno K, Naqvi Q, Kato IT, Ribeiro MS, Mylonakis E, Tegos GP, Hamblin MR. Effect of virulence factors on the photodynamic inactivation of *Cryptococcus neoformans*. PLoS ONE. 2013;8(1):e54387. PMID: 23349872 PMCID: PMC3548784
160. Kato IT, Prates RA, Sabino CP, Fuchs BB, Tegos GP, Mylonakis E, Hamblin MR, Ribeiro MS. Antimicrobial photodynamic inactivation inhibits *Candida albicans* virulence factors and reduces in vivo pathogenicity. Antimicrob Agents Chemother. 2013;57(1):445-51. PMID: 23129051 PMCID: PMC3535901
161. Neely LA, Audeh M, Phung NA, Min M, Suchocki A, Plourde D, Blanco M, Demas V, Skewis LR, Anagnostou T, Coleman JJ, Wellman P, Mylonakis E, Lowery TJ. T2 magnetic resonance enables nanoparticle-mediated rapid detection of candidemia in whole blood. Sci Transl Med. 2013;5(182):182ra54. PMID: 23616121
162. Chiebebe J, Sabino CP, Tan X., Junqueira JC, Wang Y, Fuchs BB, Jorge A, Tegos GT, Hamblin MR, Mylonakis E. Selective photoinactivation of *Candida albicans* in the non-vertebrate host infection model *Galleria mellonella*. BMC Microbiology. 2013;13(1):217.
163. Ziakas PD, Thapa R, Rice LB, Mylonakis E. Trends and significance of VRE colonization in the ICU: A meta-analysis of published studies. PLoS ONE. 2013;8(9):e75658
164. Arvanitis M, Glavis-Bloom J, Mylonakis E. Invertebrate models of fungal infection. Biochim Biophys Acta. 2013;1832(9):1378-83. PMID:23517918.
165. Arvanitis M, Mylonakis E. *C. elegans* for anti-infective discovery. Curr Opin Pharmacol. 2013;13(5):769-774.
166. Chen R, Li X, Lu S, Ma T, Huang X, Mylonakis E, Liang Y, Xi L. Role of extracellular signal-regulated kinases 1 and 2 and p38 mitogen-activated protein kinase pathways in regulating replication of *Penicillium marneffei* in human macrophages. Microbes Infect. 2014;16(5):401-8.
167. Borghi E, Romagnoli S, Fuchs BB, Cirasola D, Perdoni F, Tosi D, Braidotti P, Bulfamante G, Morace G, Mylonakis E. Correlation between *Candida albicans* biofilm formation and invasion of the invertebrate host *Galleria mellonella*. Future Microbiol. 2014 Feb;9:163-73.
168. Ziakas PD, Anagnostou T, Mylonakis E. The prevalence and significance of MRSA colonization at admission in the general ICU setting: A meta-analysis of published studies. Crit Care Med. 2014;42(2):433-44.

169. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis T, Carneiro H, Glavis-Bloom J, Coleman JJ, Mylonakis E. Fusarium infection: Report of 26 cases and review of 97 cases from the literature. *Medicine (Baltimore)*. 2013;92(6):305-16. PMID: 24145697
170. Li DD, Xu Y, Zhang D, Quan H, Mylonakis E, Hu DD, Li MB, Zhao LX, Zhu LH, Wang Y, Jiang YY. Fluconazole assists berberine to kill fluconazole-resistant *Candida albicans*. *Antimicrob Agents Chemother*. 2013;57(12):6016-27. PMID: 24060867
171. Ziakas PD, Karsaliakos P, Prodromou ML, Mylonakis E. Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies. *Biomarkers*. 2013;18(7):625-31. PMID: 24059848
172. Ziakas PD, Prodromou ML, Houry JE, Zintzaras E, Mylonakis E. The Role of TLR4 896 A>G and 1196 C>T in Susceptibility to Infections: A Review and Meta-Analysis of Genetic Association Studies. *PLoS ONE*. 2013 25;8(11):e81047. PMID: 24282567
173. Ziakas PD, Anagnostou T, Mylonakis E. The prevalence and significance of MRSA colonization at admission in the general ICU setting: A meta-analysis of published studies. *Crit Care Med*. 2014;42(2):433-44.
174. Ziakas PD, Kourbeti I, Mylonakis E. Systemic Antifungal prophylaxis after hematopoietic stem cell transplantation: A meta-analysis. *Clin Ther*. 2014;36(2):292-306.e1. PMID: 24439393
175. Prodromou ML, Ziakas PD, Poulou LS, Karsaliakos P, Thanos L, Mylonakis E. FDG-PET is a robust tool for the diagnosis of spondylodiscitis: A meta-analysis of diagnostic data. *Clin Nucl Med*. 2014;39(4):330-5.
176. Anagnostou T, Arvantis M, Kourkoumpetis T, Desalermos A, Carneiro H, Mylonakis E. Nocardiosis of the central nervous system: Experience from a general hospital and review of 84 cases. *Medicine (Baltimore)*. 2014;93(1):19-32. PMID: 24378740
177. Borghi E, Romagnoli S, Fuchs BB, Cirasola D, Perdoni F, Tosi D, Braidotti P, Bulfamante G, Morace G, Mylonakis E. Correlation between *Candida albicans* biofilm formation and invasion of the invertebrate host *Galleria mellonella*. *Future Microbiol*. 2014;9:163-73.
178. Zervou F, Zacharioudakis I, Ziakas PD, Mylonakis E. MRSA colonization and risk of infection in the neonatal and pediatric ICU: A meta-analysis. *Pediatrics*. 2014;133(4):e1015-23. PMID:24616358
179. Ziakas PD, Mylonakis E. ACP Journal Club. Probiotics did not prevent antibiotic-associated or *C. difficile* diarrhea in hospitalized older patients. *Ann Intern Med*. 2014 Jun 17;160(12):JC6. PMID: 24935512
180. Rajamuthiah R, Fuchs BB, Jayamani E, Kim Y, Larkins-Ford J, Conery A, Ausubel FM, Mylonakis E. Whole animal automated platform for drug discovery against multi-drug resistant *Staphylococcus aureus*. *PLoS ONE*. 2014;19;9(2):e89189. PMID: 24586584
181. Li DD, Zhao LX, Mylonakis E, Hu GH, Zou Y, Huang TK, Yan L, Wang Y, Jiang YY. In vitro and in vivo activity of pterostilbene against *Candida albicans* biofilms. *Antimicrob Agents Chemother*. 2014;58(4):2344-55. PMID: 24514088

182. Arvanitis M, Anagnostou T, Kourkoumpetis T, Ziakas PD, Mylonakis E. The impact of antimicrobial resistance and aging in VAP outcomes: Experience from a large tertiary care center. PLoS ONE. 2014;9(2):e89984. PMID: 24587166
183. Kourbeti I, Ziakas PD, Mylonakis E. Biological therapies in rheumatoid arthritis and the risk of opportunistic infections: A meta-analysis. Clin Infect Dis 2014;58(12):1649-57.
184. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490-526.
185. Tan X, Fuchs BB, Wang Y, Chen W, Yuen GJ, Chen RB, Jayamani E, Anastassopoulou C, Pukkila-Worley R, Coleman JJ, Mylonakis E. The role of *Candida albicans* SPT20 in filamentation, biofilm formation and pathogenesis. PLoS One. 2014;9(4):e94468. PMID: 24732310
186. Ziakas PD, Pliakos E, Zervou F, Knoll B, Rice LB, Mylonakis E. MRSA and VRE colonization in solid organ transplantation: A meta-analysis of published studies. Am J Transplant. 2014;14(8):1887-94. PMID: 25040438
187. Zacharioudakis IM, Zervou F, Ziakas PD, Mylonakis E. Meta-analysis of MRSA colonization and risk of infection in dialysis patients. J Am Soc Nephrol. 2014;25(9):2131-41. PMID: 24652802
188. Zacharioudakis IM, Ziakas PD, Mylonakis E. *Clostridium difficile* infection in the hematopoietic unit: A meta-analysis of published studies. Biol Blood Marrow Transplant. 2014;20(10):1650-4. PMID: 24914822
189. Zacharioudakis IM, Zervou FN, Ziakas PD, Rice LB, Mylonakis E. VRE Colonization among dialysis patients: A meta-analysis of prevalence, risk factors and significance. Am J Kidney Dis. 2015;65(1):88-97. PMID: 25042816
190. Zervou F, Zacharioudakis IM, Ziakas PD, Rich JD, Mylonakis E. Prevalence of and risk factors for methicillin-resistant *Staphylococcus aureus* colonization in HIV infection: A Meta-Analysis of studies. Clin Infect Dis. 2014;59(9):1302-11. PMID: 25031291
191. Luther MK, Arvanitis M, Mylonakis E, LaPlante KL. Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming *Enterococcus faecalis* or *E. faecium* in an in vitro pharmacodynamic model using simulated endocardial vegetations and in vivo survival assay using *Galleria mellonella* larvae. Antimicrob Agents Chemother. 2014 Aug;58(8):4612-20. PMID: 24867993.
192. Arvanitis M, Zacharioudakis IM, Zervou F, Ziakas PD, Fuchs B, Caliendo A, Mylonakis E. Polymerase chain reaction in the diagnosis of invasive aspergillosis: A meta-analysis of diagnostic performance. J Clin Microbiol. 2014;52(10):3731-42. PMID: 25122854
193. Zacharioudakis IM, Zervou F, Arvanitis M, Ziakas PD, Mermel LA, Mylonakis E. Antimicrobial lock solutions as a method to prevent central line-associated bloodstream infections: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59(12):1741-9. PMID: 25156111

194. Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. *Clostridium difficile* infection: An undeniably common problem among hematopoietic transplant recipients. [letter] Int J Hematol. 2014 Nov;100(5):514-5. PMID: 25139684
195. Huang X, Li D, Xi L, Mylonakis E. *Caenorhabditis elegans*: A Simple Nematode Infection Model for *Penicillium marneffe*. PLoS One. 2014;9(9):e108764.
196. Ziakas PD, Zacharioudakis IM, Mylonakis E. Graft-versus-host disease prophylaxis after transplantation: A network meta-analysis. PLoS ONE. 2014;9(12):e114735
197. Knoll B, Mylonakis E. Antibacterial bio-agents based on principles of bacteriophage biology - an overview. Clin. Infect Dis. 2014;58(4):528-34. PMID: 24270166
198. Rajamuthiah R, Mylonakis E. Effector triggered immunity activation of innate immunity in metazoans by bacterial effectors. Virulence. 2014;5(7):697-702. PMID: 25513770
199. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490-526.
200. Jayamani E, Mylonakis E. Effector triggered manipulation of host immune response elicited by different pathotypes of *Escherichia coli*. Virulence. 2014;5(7):733-9. PMID: 25513774
201. Desalermos A, Tan X, Muthiah R, Arvanitis M, Wang Y, Li D, Kourkoumpetis TK, Fuchs BB, Mylonakis E. A Multi-host approach for the systematic analysis of virulence factors in *Cryptococcus neoformans*. J Infect Dis. 2015;211(2):298-305. PMID: 25114160
202. Zervou FN, Zacharioudakis IM, Mylonakis E. ACP Journal Club. 6 weeks of antibiotics was non-inferior to 12 weeks for clinical cure in pyogenic vertebral osteomyelitis. Ann Intern Med. 2015; 19;162(10):JC7. doi: 10.7326/ACPJC-2015-162-10-007. PMID: 25984880
203. Ziakas PD, Zacharioudakis IM, Zervou F, Mylonakis E. MRSA prevention strategies in the intensive care unit: A clinical decision analysis. Crit Care Med. 2015;43(2):382-93. PMID: 25377019
204. Hu Y, Huang X, Lu S, Hamblin MR, Mylonakis E, Zhang J, Xi L. Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on *Fonsecaea monophora* in vitro. Mycopathologia. 2015;179;(1-2):103-9. PMID: 25366276
205. Grigoras CA, Ziakas PD, Jayamani E, Mylonakis E. ATG16L1 and IL23R Variants and genetic susceptibility to Crohn's disease: Mode of inheritance based on meta-analysis of genetic association studies. Inflamm Bowel Dis. 2015;21(4):768-76. PMID: 25738374
206. Cameron DR, Mortin LI, Rubio A, Mylonakis E, Moellering RC, Eliopoulos GM, Peleg AY. Impact of daptomycin resistance on *Staphylococcus aureus* virulence. Virulence. 2015;6(2):127-31. PMID: 25830650
207. Paudel S, Zacharioudakis IM, Zervou F, Ziakas PD, Mylonakis E. Prevalence of *C. difficile* infection among solid organ transplant recipients: A meta-analysis of published studies. PLoS ONE. 2015;10(4):e0124483. PMID: 25886133

208. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial. *Clin Infect Dis*. 2015;60(6):892-9. PMID: 25586686
209. Ziakas PD, Zacharioudakis IM, Zervou F, Grigoras CA, Pliakos EE, Mylonakis E. Asymptomatic carriers of toxigenic *C. difficile* in long-term care facilities: A meta-analysis of prevalence and risk factors. *PLoS ONE*. 2015;10(2):e0117195. PMID: 25707002
210. Jayamani E, Rajamuthiah R, Larkins-Ford J, Fuchs B, Conery A, Vilcinskas A, Ausubel F, Mylonakis E. Insect-derived cecropins display activity against *Acinetobacter baumannii* in a whole-animal high-throughput *Caenorhabditis elegans* model. *Antimicrob Agents Chemother*. 2015;59(3):1728-37. PMID: 25583713
211. Rajamuthiah R, Burgwyn Fuchs B, Conery AL, Kim W, Jayamani E., Kwon B, Ausubel FM, Mylonakis E. Repurposing salicylanilide anthelmintic drugs to combat drug resistant *Staphylococcus aureus* *PLoS ONE*. 2015;10(4):e0124595. PMID: 2589761
212. Zacharioudakis IM, Zervou FN, Pliakos EE, Ziakas PD, Mylonakis E. Colonization with toxinogenic *C. difficile* upon hospital admission and risk of infection: A systematic review and meta-analysis. *Am J Gastroenterol*. 2015;110(3):381-90. PMID: 25732416
213. Kim W, Conery AL, Rajamuthiah R, Burgwyn Fuchs B, Ausubel FM, Mylonakis E. Identification of an antimicrobial agent effective against methicillin-resistant *Staphylococcus aureus* persists using a fluorescence-based screening strategy. *PLoS One*. 2015;10(6):e0127640. PMID: 26039584
214. Rajamuthiah R, Jayamani E, Conery AL, Burgwyn Fuchs B, Kim W, Johnson T, Vilcinskas A, Ausubel FM, Mylonakis E. A defensin from the model beetle *Tribolium castaneum* acts synergistically with telavancin and daptomycin against multidrug resistant *Staphylococcus aureus*. *PLoS ONE*. 2015;10(6):e0128576. PMID: 26062137
215. Siettos CI, Anastassopoulou C, Russo L, Grigoras C, Mylonakis E. Modeling the 2014 Ebola virus epidemic – Agent-based simulations, temporal analysis and future predictions for Liberia and Sierra Leone. *PLoS Curr*. Mar 9;7. pii: ecurrents.outbreaks.8d5984114855fc425e699e1a18cdc6c9. PMID: 26064785
216. Huang X, Li D, Xi L, Mylonakis E. *Galleria mellonella* larvae as an infection model for *Penicillium marneffei*. *Mycopathologia* 2015;180(3-4):159-64. PMID: 26003722
217. Rossoni RD, Barbosa JO, Vilela SFG, dos Santos JD, de Barros PP, Prata MC, Anbinder AL, Fuchs B, Jorge AOC, Mylonakis E, Junqueira JC. Competitive interactions between *C. albicans*, *C. glabrata* and *C. krusei* during biofilm formation and development of experimental candidiasis. *PLoS ONE* 2015 6;10(7):e0131700. PMID: 26146832
218. Arvanitis M, Anagnostou T, Mylonakis E. Galactomannan and PCR based screening for invasive aspergillosis among high-risk hematology patients: a diagnostic meta-analysis. *Clin Infect Dis*. 2015;15;61(8):1263-72. PMID: 26157047
219. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM,

- Kontoyiannis DP, Pappas PG. Reply to Bauer and Goff. [letter] Clin Infect Dis. 2015;61(3):487-8. PMID: 25944341
220. Souza ACR, Fuchs BB, Pinhati HMS, Siqueira A, Hagen F, Meis JF, Mylonakis E, Colombo AL. *Candida parapsilosis* resistance to fluconazole: molecular mechanisms and *in vivo* impact in infected *Galleria mellonella* larvae. Antimicrob Agents Chemother. 2015 ;59(10):6581-7. PMID: 26259795
 221. Rajamuthiah R, Jayamani E, Majed H, Conery AL, Kim W, Kwon B, Fuchs BB, Kelso MJ, Ausubel FM, Mylonakis E. Antibacterial properties of 3-(Phenylsulfonyl)-2-pyrazinecarbonitrile. Bioorg Med Chem Lett. 2015;25(22):5203-7. PMID: 26459212
 222. Karanika S, Zacharioudakis IM, Zervou F, Mylonakis E. Risk Factors for meticillin-resistant *Staphylococcus aureus* colonization in dialysis patients: a meta-analysis J Hosp Infect. 2015;91(3):257-63. PMID: 26428959
 223. Fuchs BB, Li Y, Li D, Johnson T, Hendricks G, Li G, Rajamuthiah R, Mylonakis E. Micafungin elicits an immunomodulatory effect in *Galleria mellonella* and mice. Mycopathologia 2016;181(1-2):27. PMID: 26384671
 224. Arvanitis M, Mylonakis E. Diagnosis of invasive aspergillosis: recent developments and ongoing challenges. Eur J Clin Invest. 2015;45(6):646-52. PMID: 25851301
 225. Arvanitis M, Mylonakis E. Characteristics, clinical relevance and the role of echinocandins in fungal-bacterial interactions. Clin Infect Dis. 2015;1:61 Suppl 6:S630-4. PMID: 26567281
 226. Kostoulias X, Murray G, Cerqueira G, Kong J, Bantun F, Mylonakis E, Khoo C, Peleg A. The impact of a cross-kingdom signalling molecule of *Candida albicans* on *Acinetobacter baumannii* physiology. Antimicrob Agents Chemother 2015;60(1):161-7. PMID: 26482299
 227. Govindan JA, Jayamani E, Zhang X, Mylonakis E, Ruvkun G. A dialogue between *E. coli* free radical pathways and the mitochondria of *C. elegans*. Proc Natl Acad Sci USA. 2015;112(40):12456-61. PMID: 26392561
 228. Siettos CI, Anastassopoulou C, Russo L, Grigoras C, Mylonakis E. Forecasting and control policy assessment for the Ebola virus disease (EVD) epidemic in Sierra Leone using small-world networked model simulations. BMJ Open 2016;6(1):e008649. PMID: 26826143
 229. Govindan JA, Jayamani E, Zhang X, Breen P, Larkins-Ford J, Mylonakis E, Ruvkun G. Lipid signalling couples translational surveillance to systemic detoxification in *Caenorhabditis elegans*. Nature Cell Biol. 2015;17(10):1294-303. PMID: 26322678
 230. Dolla NK, Chen C, Larkins-Ford J, Rajamuthiah R, Jagadeesan S, Conery AL, Ausubel FM, Mylonakis E, Bremner JB, Lewis K, Kelso MJ. On the mechanism of berberine-INF55 (5-Nitro-2-Phenylindole) hybrid antibacterials. Aust J. Chem. 2015;67:1471-1480. PMID: 26806960
 231. Burgwyn Fuchs B, Rajamuthiah R, Remondi Souza AC, Junqueira JC, Rice LB, Mylonakis E. Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. Future Med Chem 2016;8(2):117-32. PMID: 26808006

232. Karanika S*, Paudel S*, Zervou FN, Grigoras C, Zacharioudakis IM, Mylonakis E. Prevalence and clinical outcomes of *Clostridium difficile* infection in the intensive care unit: A systematic review and meta-analysis. *Open Forum Infect Dis*. 2015;3(1):ofv186. PMID: 26788544
233. Zervou FN, Zacharioudakis IM, Pliakos EE, Grigoras CA, Ziakas PD, Mylonakis E. Adaptation of cost analysis studies in practice guidelines. *Medicine[Baltimore]* 2015;94(52):e2365. PMID: 26717377
234. Muhammed M, Arvanitis M, Mylonakis E. Whole animal HTS of small molecules for antifungal compounds. *Expert Opin Drug Discov*. 2016;11(2):117-84. PMID: 26593386
235. Liu Y, Huang X, Yi X, He Y, Mylonakis E, Xi L. Detection of *Talaromyces marneffeii* from fresh tissue of an inhalational murine pulmonary model using nested. PCR. *PLoS ONE*. 2016;11(2):e0149634. PMID: 26886887
236. Kim W, Fricke N, Conery AL, Fuchs BB, Rajamuthiah R, Jayamani E, Vlahovska PM, Ausubel FM, Mylonakis E. NH125 kills methicillin-resistant *Staphylococcus aureus* persists by lipid bilayer disruption. *Future Med Chem*. 2016;8(3):257-69. PMID: 26910612
237. Mylonakis E, Podsiadlowski L, Muhammed M, Vilcinskas. Diversity, evolution and medical applications of insect antimicrobial peptides. *Philos Trans R Soc Lond B Biol Sci*. 2016;371(1695). PMID: 27160593
238. Karanika S, Karantanos T, Arvanitis M, Grigoras C, Mylonakis E. Fecal colonization with extended-spectrum beta-lactamase-producing *Enterobacteriaceae* and risk factors among healthy individuals: A systematic review and meta-analysis *Clin Infect Dis*. 2016;63(3):310-8. PMID: 27143671
239. Tan X, Chen R, Zhu S, Wang H, Yan D, Zhang X, Farmakiotis D, Mylonakis E. *Candida albicans* airway colonization facilitates subsequent *Acinetobacter baumannii* pneumonia in a rat model. *Antimicrob Agents Chemother*. 2016;60(6):3348-54. PMID: 27001817
240. Arvanitis M, Li G, Li D, Cotnoir D, Ganley-Leal L, Carney DW, Sello JK, Mylonakis E. A conformationally constrained cyclic acyldepsipeptide is highly effective in mice infected with methicillin-susceptible and -resistant *Staphylococcus aureus*. *PLoS ONE*. 2016;11(4):e0153912. PMID: 27101010
241. Karanika S*, Kinamon T*, Grigoras C, Mylonakis E. Colonization with methicillin-resistant *Staphylococcus aureus* and risk for infection among asymptomatic athletes: a systematic review and meta-analysis. *Clin Infect Dis*. 2016;63(2):195-204. PMID: 27090988
242. Tan X, Zhu S, Yan D, Chen W, Chen R, Zou J, Yan J, Zhang X, Farmakiotis D, Mylonakis E. *Candida* spp. airway colonization: A potential risk factor for *Acinetobacter baumannii* ventilator-associated pneumonia. *Med Mycol*. 2016;54(6):557-66. PMID: 27001670
243. Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E Clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs: A systematic review and meta-analysis. *Antimicrob Agents Chemother*. 2016;60(8):4840-52. PMID: 27246783

244. Grigoras C, Zervou F, Zacharioudakis IM, Mylonakis E. Isolation of *C. difficile* carriers alone and as part of a bundle approach for the prevention of *Clostridium difficile* infection (CDI): A mathematical model based on clinical study data. PLoS ONE. 2016;11(6):e0156577. PMID: 27258068
245. Flokas M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. J Infection. 2016;Pii:S0163-4453(16)30178-5. (Epub ahead of print) PMID: 27475789
246. Ziakas PD, Joyce N, Zacharioudakis IM, Zervou FN, Besdine RW, Mor V, Mylonakis E. Prevalence and impact of *Clostridium difficile* infection in elderly residents of long-term care facilities, 2011: A nationwide study. Medicine (Baltimore). 2016;95(31):e4187. PMID: 27495022
247. Johnston T, Hendricks G, Shen S, Chen R, Kwon B, Kelso, M, Kim W, Fuchs BB, Mylonakis E. Raf-kinase Inhibitor GW5074 shows antibacterial activity against methicillin resistant *Staphylococcus aureus* and potentiates the activity of gentamicin. Future Med Chem. 2016;8(16):1941-1952. PMID: 27652456
248. Alevizakos M, Karanika S, Detsis M, Mylonakis E. Colonization with ESBL-producing Enterobacteriaceae and risk for infection among patients with solid or hematologic malignancy: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016; Pii:S0924-8579(16)30275-8. PMID: 27746102
249. Hendricks G, Mylonakis E. Expanding the nematode model system: the molecular basis of inflammation and infection recovery in *C. elegans*. Virulence. 2016;26:1-2. PMID: 27668316
250. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The Effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis. Clin Infect Dis. 2017;64(1):15-23. PMID: 27678085
251. Coleman JJ, Komura T, Munro J, Wu P, Busanelli RR, Koehler AN, Thomas M, Wagner FF, Holson EB, Mylonakis E. The immunomodulatory activity of CAPE in *Caenorhabditis elegans* is mediated by the CED-10 (Rac-1)/PAK-1 pathway. Future Med Chem. 2016;Oct 14. (Epub ahead of print) PMID: 27739327
252. Grounta A, Harizanis P, Mylonakis E, Nychas EGJ, Panagou EZ. Investigating the effect of different treatments with lactic acid bacteria on the fate of *Listeria monocytogenes* and *Staphylococcus aureus* infection in *Galleria mellonella* larvae. PLoS ONE. 2016;11(9):e0161263. PMID: 27618619
253. Zervou FN, Zacharioudakis IM, Kurpewski J, Mylonakis E. T2 Magnetic resonance for fungal diagnosis. Methods Mol Biol. 2017;1508:305-319. PMID: 27837513
254. Alevizakos M, Detsis M, Grigoras CA, Machan JT, Mylonakis E. The impact of shortages on medication prices: Implications for shortage prevention. Drugs. 2016;76(16):1551-1558. PMID: 27770351
255. Avci P, Freire F, Banvolgyi A, Mylonakis E, Wikonkal NM, Hamblin MR. Sodium ascorbate kills *Candida albicans* in vitro via iron-catalyzed Fenton reaction: importance of oxygenation and metabolism. Future Microbiol 2016;11:1535-1547. PMID: 27855492

256. Maged M, Arvanitis M, Mylonakis E. High-throughput screening of small molecules for treating *Candida* infections. *Expert Opin Drug Discov*. 2016;11(2):177-84. PMID: 26593386
257. Detsis M, Karanika S, Mylonakis E. ICU Acquisition rate, risk factors and clinical significance of digestive tract colonization with ESBL-producing Enterobacteriaceae: A systematic review and meta-analysis. *Crit Care Med*. 2017;45(4):705-714. PMID: 28157141
258. Alevizakos M, Gaitanidis A, Nasioudis D, Tori K, Flokas M, Mylonakis E. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: A systematic review and meta-analysis. *Open Forum Infect Dis*. 2016;4(1):ofw246. PMID: 28480243
259. Alevizakos M, Farmakiotis D, Mylonakis E. Updated practice guidelines for the diagnosis and management of aspergillosis: challenges and opportunities. *J Thorac Dis*. 2016; 8(12):E1767-E1770. PMID: 28149637
260. Andreatos N, Zacharioudakis IM, Zervou FN, Muhammed M, Mylonakis E. Discrepancy between financial disclosures of authors of clinical practice guidelines and reports by industry. *Medicine[Baltimore]* 2017;96(2):e5711. PMID: 28079800
261. Flokas M, Karanika S, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in pediatric bloodstream infections: A systematic review and meta-analysis. *PLoS ONE*. 2017;12(1):e0171216. PMID: 28141845
262. Karanika S*, Grigoras C*, Flokas M, Alevizakos M, Kinamon T, Kojic M, Mylonakis E. The attributable burden of *Clostridium difficile* infection to long-term care facilities stay: A clinical study. *J Am Geriatr Soc*. 2017;65(8):1733-1740. PMID: 28306141
263. Alevizakos M, Kallias A, Flokas M, Mylonakis E. Colonization with ESBL-producing Enterobacteriaceae and risk for infection in solid organ transplantation: A review and meta-analysis. *Transpl Infect Dis*. 19(4). doi: 10.1111/tid.12718. Epub 2017 Jun 20. PMID: 28470983
264. Detsis M, Tsioutis C, Karageorgos SA, Sideroglou T, Hatzakis A, Mylonakis E. Factors associated with HIV testing and HIV treatment adherence: A systematic review. *Curr Pharm Des*. 2017;23(18):2568-2578. PMID: 283456038
265. Rossoni RD, Fuchs BB, de Barros PP, dos Santos Velloso M, Cardoso OC, Junqueira JC, Mylonakis E. *Lactobacillus paracasei* modulates the immune system of *Galleria mellonella* and protects against *Candida albicans* infection. *PLoS ONE*. 2017;12(3):e0173332. PMID: 28267809
266. Li M; Lee K; Hsu M; Nau G; Mylonakis E; Ramratnam B. Lactobacillus-derived extracellular vesicles enhance host immune responses against vancomycin-resistant enterococci. *BMC Microbiol*. 2017;17(1):66. PMID: 28288575
267. Flokas ME, Karageorgos SA, Detsis M, Alevizakos M, Mylonakis E. Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-analysis. *Int J Antimicrob Agents* 2017; 49(5):565-572. PMID: 28336313

268. Kim W, Hendricks GL, Lee K, Mylonakis E An update on *C. elegans* for preclinical drug discovery. *Expert Opin Drug Discov.* 2017;12(6):625-633. PMID: 28402221.
269. Alevizakos M, Nasioudis D, Mylonakis E Urinary tract infections due to ESBL-producing Enterobacteriaceae in renal transplant recipients: A systematic review and meta-analysis. *Transpl Infect Dis.* 2017 Dec;19(6). PMID:28803446
270. Muhammed M, Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Comparison between carbapenems and beta-lactam/beta-lactamase inhibitors in the treatment for bloodstream infections caused by ESBL-producing Enterobacteriaceae: A systematic review and meta-analysis. *Open Forum Infect Dis.* 2017;4(2):ofx099. doi: 10.1093/ofid/ofx099. PMID: 28702469
271. Gwisai T, Hollingsworth NR, Cowles S, Tharmalingam N, Mylonakis E, Fuchs BB, Shukla A. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections. *Biomed Mater.* 2017;12(4):045010. doi: 10.1088/1748-605X/aa7105. PMID: 28471351
272. Andreatos N, Flokas ME, Apostolopoulou A, Alevizakos M, Mylonakis E. The dose-dependent efficacy of cefepime in the empiric management of febrile neutropenia: A systematic review and meta-analysis. *Open Forum Infect Dis.* 2017;4(3):ofx113. doi: 10.1093/ofid/ofx113. PMID: 28761897
273. Joyce NR, Mylonakis E, Mor V. Effect of *Clostridium difficile* prevalence in hospitals and nursing homes on risk of infection. *J Am Geriatr Soc.* 2017;65(7):1527-1534. PMID: 28394408
274. Johann S, Sá N, de Lima C, Lino CI, Barbeira P, Baltazar L, Santos D, Oliveira R, Mylonakis E, Fuchs BB. Heterocycle thiazole compounds exhibit antifungal activity through increase in the production of reactive oxygen species in *Cryptococcus neoformans/Cryptococcus gattii* species complex. *Antimicrob Agents Chemoter.* 2017;61(8). pii: e02700-16. doi: 10.1128/AAC.02700-16. PMID: 28533240
275. Tharmalingam N, Jayamani E, Rajamuthiah R, Castillo D, Fuchs BB, Kelso MJ, Mylonakis E. Activity of a novel protonophore against methicillin-resistant *Staphylococcus aureus*. *Future Med Chem.* 2017;9(12):1401-1411. PMID: 28771026
276. Zheng Z, Tharmalingam N, Liu Q, Jayamani E, Kim W, Fuchs BB, Zhang R, Vilcinskas A, Mylonakis E. The synergistic efficacy of *Aedes aegypti* antimicrobial peptide cecropin A2 and tetracycline against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemoter.* 2017;61(7). pii: e00686-17. PMID: 28483966
277. Jayamani E, Tharmalingam N, Rajamuthiah R, Coleman JJ, Kim W, Okoli I, Hernandez AM, Lee K, Nau GJ, Ausubel FM, Mylonakis E. Characterization of a *Francisella tularensis-Caenorhabditis elegans* pathosystem for the evaluation of therapeutic compounds. *Antimicrob Agents Chemoter.* 2017;61(9). pii: e00310-17. PMID: 28652232
278. Alevizakos M, Mylonakis E Colonization and infection with extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in patients with malignancy *Expert Rev Anti Infect Ther.* 2017;15(7):653-661. PMID: 28659026

279. Andreatos N, Mylonakis E. ACP Journal Club. Triple therapy (clarithromycin/naproxen/oseltamivir) reduced mortality more than oseltamivir alone in severe influenza infection. *Ann Intern Med.* 2017;167(8):JC41. doi: 10.7326/ACPJC-2017-167-8-041. PMID: 29049760
280. Sartelli M, [...], Mylonakis E, [...], Catena F. The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. *World J Emerg Surg.* 2017 Aug 1;12:34. doi: 10.1186/s13017-017-0145-2. PMID: 28775763
281. Flokas ME, Alevizakos M, Shehadeh F, Andreatos N, Mylonakis E. Extended-spectrum β -lactamase-producing Enterobacteriaceae colonisation in long-term care facilities: a systematic review and meta-analysis. *Int J Antimicrob Agents.* 2017;50(5):649-656. PMID: 28782707.
282. Cabral DJ, Wurster JI, Flokas ME, Alevizakos M, Zabat M, Korry BJ, Rowan AD, Sano WH, Andreatos N, Ducharme RB, Chan PA, Mylonakis E, Fuchs BB, Belenky P. The salivary microbiome is consistent between subjects and resistant to impacts of short-term hospitalization. *Sci Rep* 2017;7(1):11040. doi: 10.1038/s41598-017-11427-2. PMID: 28887570
283. Andreatos N, Grigoras C*, Shehadeh F*, Pliakos EE, Stukides G, Port J, Flokas ME, Mylonakis E The impact of HIV infection and socioeconomic factors on the incidence of gonorrhea: A county-level, US-wide analysis. *PLoS ONE* 2017;12(9):e0183938. doi: 10.1371/journal.pone.0183938. PMID: 28863154
284. Lee K, Mylonakis E. An intestine-derived neuropeptide controls avoidance behavior in *Caenorhabditis elegans*. *Cell Rep.* 2017;20(10):2501-2512. PMID: 28877481
285. Xiao X, Feng J, Li Y, Chen Z, Shi M, Xi L, Mylonakis E, Zhang J. *Agrobacterium tumefaciens*-mediated transformation: an efficient tool for targeted gene disruption in *Talaromyces marneffeii*. *World J Microbiol Biotechnol.* 2017;33(10):183. doi: 10.1007/s11274-017-2352-0. PMID: 28948456
286. Li DD, Fuchs BB, Wang Y, Huang XW, Hu DD, Sun Y, Chai D, Jiang YY, Mylonakis E. Histone acetyltransferase encoded by *NGG1* is required for morphological conversion and virulence of *Candida albicans*. *Future Microbiol.* 2017;12:1497-1510.
287. Flokas ME, Andreatos N, Alevizakos M, Kalbasi A, Onur P, Mylonakis E. Inappropriate management of asymptomatic patients with positive urine cultures: A systematic review and meta-analysis *Open Forum Infect Dis.* 2017;20(4):ofx207. PMID: 29226170
288. Grigoras CA*, Karanika S*, Velmahos E., Alevizakos M, Flokas ME, Kaspiris-Rousellis C, Evaggelidis IN, Artelaris P, Siettos CI, Mylonakis E. Correlation of opioid mortality with prescriptions and social determinants: a cross-sectional study of Medicare enrollees. *Drugs.* 2018;78(1):111-121. PMID: 29159797
289. Rossoni RD, de Barros PP, de Alvarenga JA, Ribeiro FC, Velloso MDS, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC. Antifungal activity of clinical *Lactobacillus* strains against *Candida albicans* biofilms: identification of potential probiotic candidates to prevent oral candidiasis. *Biofouling.* 2018;34(2):212-225. PubMed PMID: 29380647.

290. Zheng Z, Liu Q, Kim W, Tharmalingam N, Fuchs BB, Mylonakis E. Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of *Staphylococcus aureus*. *Future Med Chem*. 2018;10(3):283-296. PMID: 29334249.
291. Tharmalingam N, Port J, Castillo D, Mylonakis E. Repurposing the anthelmintic drug niclosamide to combat *Helicobacter pylori*. *Sci Rep*. 2018;8(1):3701. PMID: 29487357
292. Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of methicillin resistant *Staphylococcus aureus* (MRSA) nasal screening to rule out MRSA pneumonia: A diagnostic meta-analysis with antimicrobial stewardship implications. *Clin Infect Dis*. 2018 Jan 11. doi: 10.1093/cid/ciy024. [Epub ahead of print] PubMed PMID: 29340593.
293. de Barros PP, Scorzoni L, Ribeiro FC, Fugisaki LRO, Fuchs BB, Mylonakis E, Jorge AOC, Junqueira JC, Rossoni RD. *Lactobacillus paracasei* 28.4 reduces in vitro hyphae formation of *Candida albicans* and prevents the filamentation in an experimental model of *Caenorhabditis elegans*. *Microb Pathog*. 2018;117:80-87. PMID: 29432910.
294. Baddley JW, Cantini F, Goletti D, Gómez-Reino JJ, Mylonakis E, San-Juan R, Fernández-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumour necrosis factor- α agents). *Clin Microbiol Infect*. 2018 Feb 6. pii: S1198-743X(18)30030-2. doi: 10.1016/j.cmi.2017.12.025. PMID: 29459143
295. Mylonakis E, Zacharioudakis IM, Clancy CJ, Nguyen MH, Pappas PG. The efficacy of T2 magnetic resonance assay in monitoring candidemia after the initiation of antifungal therapy: The Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) trial. *J Clin Microbiol*. 2018 Mar 26;56(4). pii: e01756-17. doi: 10.1128/JCM.01756-17. Print 2018 Apr. PMID: 29367293
296. Tharmalingam N, Rajmuthiah R, Kim W, Fuchs BB, Jeyamani E, Kelso MJ, Mylonakis E. Antibacterial properties of four novel hit compounds from a methicillin-resistant *Staphylococcus aureus*-*Caenorhabditis elegans* high-throughput screen. *Microb Drug Resist*. 2018 Feb 20. doi: 10.1089/mdr.2017.0250. [Epub ahead of print] PubMed PMID: 29461939.
297. Kim W, Hendricks G, Tori K, Fuchs BB, Mylonakis E. Strategies against methicillin-resistant *Staphylococcus aureus* persists. *Future Med Chem*. 2018 Mar 23. doi: 10.4155/fmc-2017-0199. [Epub ahead of print] PMID: 29569952
298. Tansarli GS, Mylonakis E. ACP Journal Club. Fecal microbiota transplantation by oral capsule was noninferior to colonoscopy for recurrence of *C. difficile* infection at 12 wk *Ann Intern Med*. 2018 Mar 20;168(6):JC31. doi: 10.7326/ACPJC-2018-168-6-031. No abstract available. PMID: 29554669
299. Lin S, Chen R, Zhu S, Wang H, Wang L, Zou J, Yan J, Zhang X, Farmakiotis D, Tan X, Mylonakis E. Candidemia in adults at a tertiary hospital in China: Clinical characteristics, species distribution, resistance and outcomes. *Mycopathologia*. 2018 Mar 23. doi: 10.1007/s11046-018-0258-5. [Epub ahead of print] PMID: 29572768

300. Zacharioudakis IM, Zervou FN, Mylonakis E. T2 magnetic resonance assay: Overview of available data and clinical implications. *J Fungi (Basel)*. 2018 Apr 4;4(2). pii: E45. doi: 10.3390/jof4020045. Review. PMID: 29617284
301. Araos R, Andreatos N, Ugalde J, Mitchell S, Mylonakis E, D'Agata EMC. The fecal microbiome among nursing home residents with advanced dementia and *Clostridium difficile*. *Dig Dis Sci*. 2018 Mar 28. doi: 10.1007/s10620-018-5030-7. [Epub ahead of print] PMID: 29594967
302. Andreatos N, Shehadeh F, Pliakos EE, Mylonakis E. The impact of antibiotic prescription rates on the incidence of MRSA bloodstream infections: a county-level, U.S.-wide analysis. *Int J Antimicrob Agents*. 2018 Apr 12. pii: S0924-8579(18)30105-5. doi: 10.1016/j.ijantimicag.2018.04.003. [Epub ahead of print] PMID: 29656062
303. de Sá NP, de Lima CM, dos Santos JR, da Costa MC, de Barros PP, Junqueira JC, Vaz JA, de Oliveira RB, Fuchs BB, Mylonakis E, Rosa CA, Santos DA, Johann S. A phenylthiazole derivative demonstrates efficacy on treatment of the cryptococcosis and candidiasis in animal models *Future Sci OA*. 2018 Apr 25;4(6). PMID: 30057783
304. Huang X, Liu Y, Xi L, Zeng K, Mylonakis E. *Galleria mellonella* as a model invertebrate host for the study of muriform cells of dematiaceous fungi. *Future Microbiol*. 2018 Jul 13;1021-1028. PMID: 29927339
305. Liu Q, Zheng Z, Kim W, Fuchs B, Mylonakis E. Influence of sub-inhibitory concentrations of NH125 on biofilm formation and virulence factors of *Staphylococcus aureus* *Future Med Chem*. 2018 Jun 1;10(11):1319-1331. PMID: 29846088
306. Pliakos E, Andreatos N, Ziakas PD, Mylonakis E. The cost-effectiveness of rapid diagnostic testing for the diagnosis of bloodstream infections with or without antimicrobial stewardship *Clin Microbiol Rev* 2018 May 30;31(3). PMID: 29848775
307. de Sá NP, Fátima L, de Paula LJ, Cruz LIB, TS Matos, Lino CL, de Oliveira RB, de Souza-Fagundes EM, Fuchs BB, Mylonakis E, Johann S. A bis-arylidencyclo-alkanone demonstrates efficacy against *Candida albicans* infection in oral and systemic murine models. *J Glob Antimicrob Resist*. 2018 Sep 14;287-293. PMID: 29715565
308. Zacharioudakis IM, Zervou FN, Mylonakis E. Use of T2MR in invasive candidiasis with and without candidemia. *Future Microbiol*. 2018 Aug 13;1165-1173. PMID: 29792512
309. de Sá NP; Pôssa AP; Perez P; Ferreira JM; Fonseca NC; Lino CI; Cruz LB, de Oliveira RB, Rosa CA; Borelli BM; Mylonakis E; Fuchs BB; Johann S. A Antifungal activity directed toward the cell wall by 2-cyclohexylidenhydrazo-4-phenyl-thiazole against *Candida albicans*. *Inf Dis - Drug Targets*. 2019 19;(4):428-438. PMID: 29852876
310. Ziakas PD, Kourbeti IS, Poulou LS, Vlachogeorgos GS , Mylonakis E. Medicare Part D prescribing for direct oral anticoagulants in the United States: Cost, use and the "rubber effect". *PLoS ONE*. 2018 Jun 7;13(6):e0198674. PMID: 29879194
311. Kim W, Zhu W, Hendricks GL, Van Tyne D, Steele AD, Keohane CE, Fricke N, Conery AL, Shen S, Pan W, Lee K, Rajamuthiah R, Fuchs BB, Vlahovska PM, Wuest WM, Gilmore MS, Gao H, Ausubel FM, Mylonakis E. A new class of synthetic retinoid antibiotics effective against bacterial persisters. *Nature*. 2018;556(7699):103-107. doi: 10.1038/nature26157. PMID: 29590091.

312. Bi S, Lv QZ, Wang TT, Fuchs BB, Hu DD, Anastassopoulou CG, Desalermos A, Muhammed M, Wu CL, Jiang YY, Mylonakis E, Wang Y. *SDH2* is involved in proper hypha formation and virulence in *Candida albicans*. *Future Microbiol*. 2018 Aug 13;1141-1156. PMID: 30113213
313. Tansarli GS, Mylonakis E. ACP Journal Club. Procalcitonin-guided antibiotic treatment did not reduce antibiotic use in suspected lower respiratory tract infection in the ED. *Ann Intern Med*. 2018 Oct 16;169(8):JC39. doi: 10.7326/ACPJC-2018-169-8-039. No abstract available. PMID: 30326083
314. Tansarli GS, Mylonakis E Efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults: A systematic review and meta-analysis. *Antimicrob Agents Chemoter*. 2018 Aug 27;62(9). PMID: 29987137
315. Johnston T, Van Tyne D, Chen RF, Fawzi NL, Kwon B, Kelso MJ, Gilmore MS, Propyl-5-hydroxy-3-methyl-1-phenyl-1H-pyrazole-4-carbodithioate (HMPC): a new bacteriostatic agent against methicillin—resistant *Staphylococcus aureus*. *Sci Rep* 2018 May 4;8(1):7062. doi: 10.1038/s41598-018-25571-w. PMID: 29728636.
316. Porrassa AMG, Terraa B, Bragaa TC, Magalhã TFF, Martins CVB, da Silva DL, Ferreira Gouveia LMB, de Freitasb GSJ, Santosb DA, Resende-Stoianof MA, Fuchs BB, Mylonakis E, de Freitasa RP, de Fátima A. Butenafine and analogues: An expeditious synthesis and cytotoxicity and antifungal activities *J Adv Res*. 2018 Jun 21;14:81-91. PMID: 30009053
317. Pliakos EE, Andreatos N, Ziakas PD, Mylonakis E. The cost-effectiveness of antimicrobial lock solutions for the prevention of central line-associated bloodstream infections. *Clin Infect Dis*. 2019 Jan 18;68(3):419-425. PMID: 29945237
318. Souza ACR, Fuchs BB, de Souza Alves V, Jayamani E, Colombo AL, Mylonakis E. Pathogenesis of the *Candida parapsilosis* complex in the model host *Caenorhabditis elegans*. *Genes (Basel)*. 2018 Aug 8;9(8). PMID: 30096852
319. Fuchs BB, Chaturvedi S, Rossini RD, de Barros PP, Torres-Velez F, Vishnu, Mylonakis E, Chaturvedi V. *Galleria mellonella* experimental model for bat fungal pathogen *Pseudogymnoascus destructans* and human fungal pathogen *Pseudogymnoascus pannorum*. *Virulence*. 2018;9(1):1539-1547. PMID: 30289352
320. Fuchs BB, Tharmalingam N, Mylonakis E. Vulnerability of long-term care facility residents to *Clostridium difficile* infection due to microbiome disruptions. *Future Microbiol* 2018 Oct;13:1537-1547. doi: 10.2217/fmb-2018-0157. Epub 2018 Oct 12. Review. PMID: 30311778
321. Kim W, Steele A, Zhu W; Csatory, E; Fricke N; Dekarske M, Jayamani E; Pan W, Kwon B, Sinitsa I, Rosen J, Conery A, Fuchs BB, Vlahovska P, Ausubel FM, Gao H, Wuest W, Mylonakis E. Discovery and optimization of nTZDpa as an antibiotic effective against bacterial persisters. *ACS Infect Dis*. 2018 Nov 9;4(11):1540-1545. PMID: 30132650
322. Kalligeros M, Mylonakis E. ACP Journal Club. Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial. *Ann Intern Med*. 2019 Jan 15;170(2):JC10. PMID: 30641561

323. Rowan-Nash A, Korry B, Mylonakis E, Belenky P. Cross-domain and viral interactions in the microbiome. *Microbiol Mol Biol Rev.* Jan 9;83(1). pii: e00044-18. doi: 10.1128/MMBR.00044-18. Print 2019 Mar. Review. PMID: 30626617
324. Cruz L, Lopes L, Ribeiro F, Sá N, Lino C, Tharmalingam N, Oliveira R, Mylonakis E, Fuchs B, Rosa C, Johann S. Anti-*Candida albicans* activity of thiazolylhydrazone derivatives in invertebrate and murine models. *J Fungi (Basel)* 2018 Dec 12;4(4). pii: E134. doi: 10.3390/jof4040134. PMID: 30545053
325. Pliakos E, Andreatos N, Tansarli G, Ziakas PD, Mylonakis E. The cost-effectiveness of corticosteroids for the treatment of community-acquired pneumonia. *Chest* 2019 Apr;155(4):787-794. doi: 10.1016/j.chest.2018.11.001. Epub 2018 Nov 15. PMID: 30448195
326. Junqueira JC, Mylonakis E. Current status and trends in alternative models to study fungal Pathogens. *J Fungi (Basel)*. 2019 Jan 26;5(1). pii: E12. doi: 10.3390/jof5010012. PMID: 30691083
327. Zacharioudakis IM, Zervou FN, Shehadeh F, Mylona EK, Mylonakis E. Association of community factors with hospital-onset *Clostridioides (Clostridium) difficile* infection: A population based U.S.-wide study *EClinicalMedicine* 2019 Feb 19;8:12-19. doi: 10.1016/j.eclinm.2019.02.001. eCollection 2019 Feb. PMID: 31193719
328. Fuchs H, Eatemadpour S, Martel-Foley JM, Stott S, Toner M, Mylonakis E. Rapid isolation and concentrate of pathogenic fungi using inertial focusing a chip-based platform. *Front Cell Infect Microbiol.* Front Cell Infect Microbiol. 2019 Feb 12;9:27. doi: 10.3389/fcimb.2019.00027. eCollection 2019. PMID: 30809512
329. Shehadeh F, Zacharioudakis IM, Zervou FZ, Mylonakis E. Cost-effectiveness of rapid diagnostic assays that perform directly on blood samples for the diagnosis of septic shock. *Diagn Microbiol Infect Dis.* 2019 Mar 3. pii: S0732-8893(18)30384-5. doi: 10.1016/j.diagmicrobio.2019.02.018. [Epub ahead of print] PMID: 30922592
330. Tansarli GS, Andreatos N, Pliakos EE, Mylonakis E. Antibiotic treatment duration for bacteremia due to Enterobacteriaceae: A systematic review and meta-analysis. *Antimicrob Agents Chemother.* 2019 Apr 25;63(5). PMID: 30803971
331. Rajasekar S*, Krishna TP*, Tharmalingam N*, Andivelu I**, Mylonakis E**. Metal-free C-H thiomethylation of quinones using iodine and DMSO and study of antibacterial activity *ChemistrySelect.* (in press).
332. Liu H, Shashank Shukla S, Vera-Gonzalez N, Tharmalingam N, Mylonakis E, Fuchs BB, Shukla A. Auranofin releasing antibacterial and antibiofilm polyurethane intravascular catheter coatings. *Front Cell Infect Microbiol.* 2019 Feb 28;9:37. doi: 10.3389/fcimb.2019.00037. eCollection 2019. PMID: 30873389
333. Zervou F, Zacharioudakis Y, Mylonakis E. Carriers of *Clostridioides (Clostridium) difficile*: To the center of focus for controlling the rate of infection. *Clin Infect Dis.* 2019 Oct 15;69(9):1645-1646. PMID: 30901033

334. Volpi C, Shehadeh F, Mylonakis E. Correlation of antimicrobial prescription rate and county income in Medicare part D. *Medicine [Baltimore]* 2019 May;98(22):e15914. doi: 10.1097/MD.00000000000015914. PMID: 31145355
335. Shehadeh F, Zacharioudakis IM, Zervou FZ, Mylonakis E. Cost-effectiveness of molecular diagnostic assays for the therapy of severe sepsis and septic shock in the emergency department. *PLoS ONE* 2019 May 24;14(5):e0217508. doi: 10.1371/journal.pone.0217508. eCollection 2019. PMID: 31125382
336. Feng, J, Chen Z, He L, Xiao X, Chen C, Chu J, Mylonakis E, Xi L. *AcuD* gene knockout attenuates the virulence of *Talaromyces marneffe* in a zebrafish model. *Mycobiology*. 2019 Jun 17;47(2):207-216. PMID: 31448141
337. Kalligeros M, Shehadeh F, Karageorgos SA, Zacharioudakis IM, Mylonakis E. MRSA colonization and acquisition in the burn unit: A systematic review and meta-analysis. *Burns* 2019 Jun 12. pii: S0305-4179(18)31091-X. doi: 10.1016/j.burns.2019.05.014. [Epub ahead of print] PMID: 31202530
338. Tharmalingam N, Ribeiro NQ, da Silva DL, Cruz LIB, Shen S, dos Santos JD, Ezikovich K, D'Agata EMC, Mylonakis E, Fuchs BB Auranofin is an effective agent against clinical isolates of *Staphylococcus aureus*. *Future Med Chem*. 2019 Jun 11(12):1417-1425. PMID: 31298580
339. Poudel S, Shehadeh F, Zacharioudakis IM, Tansarli GS, Zervou FN, Kalligeros M, van Aalst R, Chit A, Mylonakis E. The effect of influenza vaccination on the mortality and risk of hospitalization in patients with heart failure: A systematic review and meta-analysis *Open Forum Infect Dis*. 2019 Apr 2;6(4):ofz159. doi: 10.1093/ofid/ofz159. eCollection 2019 Apr. PMID: 31041354
340. Nguyen MH, Clancy CJ, Pasculle AW, Pappas PG, Alangaden G, Pankey GA, Schmitt BH, Altaf Rasool A, Weinstein MP, Widen R, Hernandez DR, Wolk DM, Walsh TJ, Perfect JR, Wilson MN, Mylonakis E. Performance of the T2Bacteria panel for diagnosing bloodstream infections. A diagnostic accuracy study. *Ann Intern Med*. 2019 May 14. doi: 10.7326/M18-2772. [Epub ahead of print] PMID: 31083728
341. Cheng A, Kim W, Escobar I, Mylonakis E, Wuest W. Structure-Activity Relationship and Anticancer Profile of Second-Generation Anti-MRSA Synthetic Retinoids. *ACS Med Chem Lett*. (in press)
342. Tharmalingam N, Khader R, Fuchs BB, Mylonakis E. The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-Resistant *Staphylococcus aureus*. *Front Microbiol*. 2019 Jul 17;10:1557. doi: 10.3389/fmicb.2019.01557. PMID: 31379761
343. Kalligeros M, Karageorgos SA, Shehadeh F, Zacharioudakis IM, Mylonakis E. The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: A systematic review and meta-analysis. *Antimicrob Agents Chemother*. 2019 Oct 7. PMID: 31591125
344. Kim W, Zou G, Hari TPA, Wilt IK, Zhu W, Galle N, Faizi HA, Hendricks GL, Tori K, Pan W, Huang X, Steele AD, Csatory EE, Dekarske MM, Rosen JL, Ribeiro NQ, Lee K, Port J, Fuchs BB, Vlahovska PM, Wuest WM, Gao H, Ausubel FM, Mylonakis E. A selective

- membrane-targeting repurposed antibiotic with activity against persistent methicillin-resistant *Staphylococcus aureus*. Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16529-16534. doi: 10.1073/pnas.1904700116. PMID: 31358625
345. Volpi C, Shehadeh F, Mylonakis E. The Role of County-Level Socioeconomic Status on Brand-name Prescriptions in Medicare Part D: A Cross-sectional Study. Medicine [Baltimore]. 2019 May 98(22):e15914. PMID: 31145355
 346. Mylona EK, Shehadeh F, Fleury E, Kalligeros M, Mylonakis E. Neighborhood-level analysis on the impact of accessibility to fast food and open green spaces on the prevalence of obesity. Am J Med. 2019 Oct 15. Pii: S0002-9343(19)30747-8. PMID: 31626745
 347. Kalligeros M, Shehadeh F, Mylona EK, Depaah Afriyie C, van Aalst R, Chit A, Mylonakis E Influenza vaccine effectiveness against influenza-associated hospitalization in children: A systematic review and meta-analysis. Vaccine (in press).
 348. Wang L, Chen R, Weng Q, Lin S, Wang H, Li L, Fuchs BB, Tan X*, Mylonakis E*. *SPT20* regulates the Hog1-MAPK pathway and is involved in *Candida albicans* response to hyperosmotic stress. Front Microbiol. (in press). *Shared senior authorship
 349. Ziakas PD, Mylonakis E Web search popularity, publicity, and utilization of direct oral anticoagulants in the United States, 2008-2018: A STROBE-compliant study. Medicine [Baltimore] (in press).
 350. Tori K, Tansarli GS, Parente DM, Kalligeros M, Ziakas PD, Mylonakis E The Cost-Effectiveness of Empirical Antibiotic Treatments for High-Risk Febrile Neutropenic Patients: A Decision Analytic Model. Medicine [Baltimore] (in press).
 351. Ribeiro FC, Junqueira JC, Dos Santos JD, de Barros PP, Rossoni RD, Shukla S, Fuchs BB, Shukla A, Mylonakis E. Development of probiotic formulations for oral candidiasis prevention: Gellan gum as a carrier to deliver *Lactobacillus paracasei* 28.4. Antimicrob Agents Chemother. 2020 Apr 6. pii: AAC.02323-19. doi: 10.1128/AAC.02323-19. [Epub ahead of print] PMID: 32253208
 352. Cheng AV, Kim W, Escobar IE, Mylonakis E, Wuest WM. Structure-Activity Relationship and Anticancer Profile of Second-Generation Anti-MRSA Synthetic Retinoids. ACS Med Chem Lett. 2019 Jul 17;11(3):393-397. doi: 10.1021/acsmchemlett.9b00159. eCollection 2020 Mar 12. PMID: 32184975
 353. Tori K, Kalligeros M, Shehadeh F, Khader R, Nanda A, van Aalst R, Chit A, Mylonakis E. The Process of Obtaining Informed Consent to Research in Long Term Care Facilities (LTCFs): An Observational Clinical Study. Medicine [Baltimore] (in press).
 354. Kalligeros M, Zacharioudakis IM, Tansarli GS; Tori K, Shehadeh F, Mylonakis E. In-depth analysis of T2Bacteria positive results in patients with concurrent negative blood culture: a case series. BMC Infectious Diseases (in press).
 355. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, Mylonakis E.. Association of Obesity with Disease Severity among Patients with COVID-19. Obesity (in press).
 356. Bose R; Nagendran T; Garcia Marques F, Sukumar UK, Natarajan A, Zeng Y, Robinson E, Bermudez A, Chang E, Habte F, Pitteri S, McCarthy J, Gambhir S, Massoud T, Mylonakis E.

Paulmurugan R. Reconstructed apoptotic bodies as targeted ‘nano decoys’ to treat intracellular bacterial infections within macrophages and cancer cells ACS Nano (in press).

Book Chapters, Clinical Guidelines and Reports

357. Wang Y, Li D, Jiang YY, Mylonakis E (Authors). Utility of insects for studying human pathogens and evaluating new antimicrobial agents. Publisher: Springer-Verlag Berlin Heidelberg, (in press).
358. Endocarditis. Part of a database of teaching handouts at the MGH. The file was created by Dr. Oemer Goek on July 04, 2007 (last modified in January, 2009). I serve as faculty advisor. The document is available on the MGH Partners Hub Intranet.
359. Mylonakis E, Syriopoulou V. Babesiosis. In: Griffith’s 5-Minute Clinical Consult, ninth edition. Lipincott Williams and Wilkins, Philadelphia, PA (authored and updated this book chapter for the last 5 years).
360. Muhammed M, Coleman JJ, Mylonakis E. *Caenorhabditis elegans*: A nematode infection model for pathogenic fungi. In: Host-Fungus Interactions (Methods in Molecular Biology, Vol. 845). Brand, Alexandra C.; MacCallum, Donna M. (Eds.)
361. Kourkoumpetis T & Mylonakis E (Contributors) Critical Care – Secrets, 5th Edition. Chapter 35, Disseminated Fungal Infections. Mosby-Elsevier, St. Louis, Missouri, 2013.
362. Karsaliakos PM, Mylonakis E. Listeriosis. ePOCRATES
363. Cunha CB, Mylonakis E. Infection of the heart and blood vessels. Andreoli and Carpenter’s Cecil Essentials of Medicine By Ivor Benjamin, Robert C. Griggs, Edward J Wing, J. Gregory Fitz. 2015
364. Johnson J, Mylonakis E. *Listeria monocytogenes* and Human Listeriosis. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Disease 9th edition.
365. Kim W, Escobar I, Fuchs BB, Mylonakis E. Antimicrobial drug discovery against persisters. In: Persisters, Springer, 2019.

Editor (Books/Textbooks)

Gorbach SL (Editor), Falagas M (Editor). Mylonakis E (Associate Editor), Stone D (Associate Editor). The 5-Minute Infectious Disease Consult. Publisher: Lipincott Williams and Wilkins. Philadelphia, PA: Lipincott Williams and Wilkins;2001.

Mylonakis E & Rich JD (Authors). Infectious Disease Trial Reviews. Publisher: LeJacq Communications, Inc Greenwich, CT, 2001.

Mylonakis E & Gorbach SL (Authors). Electronic Manual on “Treatment of Infectious Diseases.” 2007.

Falagas M & Mylonakis E (Editors) The 5-Minute Infectious Disease Consult. Publisher: Lipincott Williams and Wilkins. Philadelphia, PA: Lipincott Williams and Wilkins; 2011.

Mylonakis E, Ausubel FM, Casadevall A, Gilmore M (Editors) Model Hosts (Advances in Experimental Medicine and Biology, Vol. 710). Publisher: Springer,. New York, NY, 2011.

Tegos G & Mylonakis E (Editors) Antimicrobial Drug Discovery, Emerging Strategies. Publisher: Centre for Agriculture and Biosciences International, Oxfordshire, United Kingdom, 2012.

LaPlante K, Cunha C, Morrill H, Rice LB & Mylonakis E Antimicrobial Stewardship: Principles & Practice Centre for Agriculture and Biosciences International, Oxfordshire, United Kingdom, 2017.

Metrics

<https://scholar.google.com/citations?hl=en&user=7Sa6XgEAAAAJ>

Citation indices	All	Since 2015
Citations	20,660	11,107
h-index	76	55
i10-index	241	217

Patents

1. Ausubel FM, Calderwood SB, Mylonakis EE, Diener A, Plotnikova J, Sifri CD, Rahme LG, Tan M-W, Ruvkun GB, Jander G, Heard J. Methods of screening compounds useful for prevention of infection or pathogenicity. US patent 6,905,670, 2005 June 14.

This innovation outlines screening procedures for identifying compounds useful for inhibiting fungal and bacterial infection and pathogenicity. Also, methods are also disclosed for identifying fungal virulence factors. My contribution focused on the implementation of invertebrate model hosts for the study of fungal infections and pathogenicity. This approach is now used in more than 10 different research laboratories around the world for the study of microbial pathogenesis.

2. Ausubel FM, Calderwood SB, Garsin DA, Mylonakis E, Sifri CD. Photolyase nucleic acids. US patent 7,186,186, 2007 March 6.

This invention provides a novel approach to identifying enterococcal virulence factors and for identifying compounds for treating bacterial pathogens. The invention further provides enterococcal virulence factors that serve as targets for drug discovery.

3. Ausubel FM, Calderwood SB, Mylonakis EE. Screening methods for pathogen virulence factors under low oxygen conditions. US patent pending (PCT Publication WO 02/092007) US Patent Application 20050019259.

The invention relates to screening methods for identifying pathogen virulence factors expressed under conditions of low oxygen and for identifying drugs that are effective against anaerobic pathogens. The method includes the steps of: (a) exposing a nematode to a mutagenized pathogen cultured under a low oxygen condition; (b) determining whether the mutant pathogen infects the nematode, a reduction of disease in the nematode relative to that caused by the non-mutagenized pathogen indicating a mutation in a pathogenic virulence factor; and (c) using the mutation as a marker for identifying the pathogenic virulence factor.

4. Ausubel FM, Holson E, Mylonakis E. Modified saponins for the treatment of fungal infections. US Patent No. 9320751.

This application outlines the antifungal activity of saponin natural products alone or in combination with existing antifungal agents. The articles, patents and our work over the last decade outline the use of *C. elegans* and other alternative model hosts for the study of fungal pathogenesis.

5. Ausubel FM, Fuchs B, Kim W, Mylonakis E, Raja Muthiah. Antibacterial and antifungal compounds. US Notice of Allowance #14/620,542 March 21, 2016

This patent covers a series of compounds identified through our drug discovery assays. These compounds have high potency and low toxicity and the efficacy of these compounds against bacterial and fungal pathogens was not previously discovered.

6. Fuchs B, Junqueira J, Mylonakis E. Probiotic-directed prevention of fungal infections by a Lactobacillus strain. International Publication Number Patent WO 2018/026719 February 8, 2018

This patent application outlines the use of a specific Lactobacillus strain that can immunomodulate antifungal host responses and in order to prevent mucocutaneous candidiasis.

7. Ausubel FM, Fuchs, HB, Gao Y, Kim W., Muthiah R, Mylonakis E, Pan W, Wuest W, Mylonakis E. nTZDpa-based membrane-targeting agents against bacterial persisters. Pending

This patent covers a retinoid compounds with novel antimicrobial properties.

8. Ausubel FM, Kim W., Mylonakis E, Wuest W, Membrane-targeting agents against bacterial persisters. Pending

This patent covers a series of specific compounds and their analogs with activity against bacteria, including persister cells.

Invited Presentations

Regional

1. Prophylactic efficacy of amphotericin B, liposomal amphotericin B, itraconazole or fluconazole in *Aspergillus fumigatus* experimental endocarditis, Rhode Island Meeting of the American College of Physicians, Providence, RI, 1996
2. Attitudes of program directors in internal medicine programs towards international medical graduates. Rhode Island Meeting of the American College of Physicians, Providence, RI, 1997
3. Substance abuse is responsible for most pre-AIDS deaths among women with HIV infection in Providence, RI. Rhode Island Meeting of the American College of Physicians, Providence, RI, 1998
4. Non-mammalian systems for the study of cryptococcal pathogenesis, Boston University Department of Microbiology, Boston, MA, 2004
5. Invertebrate Models for the study of fungal pathogenesis, Colloquium on Global Infectious Diseases, Ellison Medical Foundation and the Marine Biological Laboratory, Woods Hole, MA, 2004
6. Worms, flies, and the pursuit of cryptococcal pathogenesis: Heterologous hosts and the study of cryptococcal host/pathogen interactions, Sixth International Conference on Cryptococcus & Cryptococcosis (ICCC), Boston, MA, 2005
7. Current Approaches to Fungal Pathogenesis, Marine Biological Laboratory, Woods Hole, MA, 2005
8. *C. elegans* and *G. mellonella* to study the virulence of human pathogenic fungi, Marine Biology Laboratory, Woods Hole, MA, 2006
9. Heterologous hosts and the evolution and study of microbial pathogenesis, Brown University, Infectious Disease Division, Providence, RI, 2006
10. Antifungal therapy, Medical Grand Rounds, Rhode Island Hospital, Brown University, Providence, RI, 2006
11. *C. elegans* & other Invertebrate Model Systems to Study the Biology & Pathogenesis of Human Pathogenic Fungi, University of Massachusetts, 2007
12. Molecular Mycology: Non-vertebrate animal model systems to study the virulence of human pathogenic fungi, Marine Biology Laboratory, Woods Hole, MA, 2007
13. Fungal pathogenesis: Advice from the worms, Marine Biology Laboratory, Woods Hole, MA, 2008

14. Molecular Mycology: Non-vertebrate animal model systems to study the virulence of human pathogenic fungi, Marine Biology Laboratory, Woods Hole, MA, 2009
15. Case discussion, 35th annual Infectious Diseases of Adults postgraduate course, Harvard Medical School, Fairmont Copley Plaza Hotel, Boston, MA, 2010
16. Antifungal Drug Discovery, Novartis Institutes for BioMedical Research, Cambridge, MA, 2010
17. Review for the Infectious Disease Section of the Boards, The Miriam Hospital, Providence, RI, 2010
18. Systemic Fungal Infections, Rhode Island Hospital, Brown University, Providence, RI, 2010
19. Molecular Mycology: Non-vertebrate animal model systems to study the virulence of human pathogenic fungi, Marine Biology Laboratory, Woods Hole, MA, 2010
20. Molecular Mycology: Non-vertebrate animal model systems to study the virulence of human pathogenic fungi, Marine Biology Laboratory, Woods Hole, MA, 2012
21. MSI Chalk-talk Breakfast, Asking the worms for advice: Using *C. elegans* to study fungal pathogenesis, Harvard Medical School, Boston, MA, 2013
22. *C. elegans* as a model host for the study of microbial virulence and innate immunity. COBRE Center for Stem Cell Biology Lecture, Rhode Island Hospital, Brown University, Providence, RI, 2013
23. *C. elegans* as a model host for the study of microbial pathogenesis. Tufts University, Boston, MA, 2014
24. Molecular Mycology: Model hosts: worms and insects and their similarities to apples and planets, Marine Biology Laboratory, Woods Hole, MA, 2014
25. Introduction to Infectious Diseases, Brown University, Providence, RI, 2016
26. Antimicrobial drug discovery and repurposing using a whole animal *C. elegans*-based screen, Harvard University, Cambridge, MA, 2016
27. Medicine and Infectious Diseases in the era of limited resources and microbial resistance, The Miriam Hospital, Providence, RI, 2019

National

1. Use of non-mammalian systems for the study of host/pathogen interactions, Duke University Department of Molecular Genetics and Microbiology, 2004
2. Killing of *Galleria mellonella* by *Cryptococcus neoformans* as a system for the study of yeast pathogenesis and the activity of antifungal agents, The American Society for Microbiology's, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 2005
3. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi, University of Vermont, Burlington, VT, 2007

4. The Fungal Kingdom: Diverse and essential roles in earth's ecosystem. A report from the American College of Microbiology, 2007
5. *C. elegans* and the study of fungal pathogenesis, University of Washington, Seattle, WA, 2008
6. Non-mammalian animal model systems for the study of fungal pathogenesis, 9th ASM (American Society for Microbiology) Conference on Candida and Candidiasis, Jersey City, NJ, 2008
7. *C. elegans* and the study of fungal pathogenesis, Grand Rounds National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, 2008
8. Sterilization and prevention of infection in the healthcare setting, The Harley Ross Hinton Lecture Series, Southside Regional Medical Center, Petersburg, VA, 2010
9. Case Studies from North America. Case Studies in Invasive Mycoses: International Challenges and Opportunities. A CME event from the Mycoses Study Group Educational Committee, Philadelphia, PA, 2011
10. *Microbial Virulence*, Research Seminar Series, Drexel University College of Medicine, Institute for Molecular Medicine & Infectious Disease, Philadelphia, PA, 2011
11. Invertebrate Animal Models. The American Society for Microbiology's, 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL, 2012
12. Invertebrate Models of Fungal Infection, Department of Microbiology, University of Tennessee, Knoxville, TN, 2012
13. Putting the worms to work: *C. elegans* as a heterologous host and a platform for antimicrobial drug discovery, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 2012
14. *C. elegans* as a heterologous host and a platform for antimicrobial drug discovery, Department of Medicine, University of Colorado, Denver, CO, 2012
15. Invertebrate Model Hosts for the Study of Biofilms and Bacterial-fungal Interactions, ASM Biofilms Meeting, Miami, Florida, 2012
16. New Approaches in the Treatment of Fungal Infections, 52nd ICAAC Meeting, San Francisco, CA, 2012
17. Heterologous Hosts for Microbial Pathogenesis, FASEB Science Research Conference, Snowmass Village, CO, 2013
18. Bacterial-fungal interactions in *C. elegans*. 46th Annual Meeting of the Society for Invertebrate Pathology, Pittsburgh, PA, 2013

International

1. Laboratory testing for infection with the human immunodeficiency virus, University of Crete, Greece, 2002
2. Antifungal therapies, Medical Grand Rounds, Hygeia Hospital, Athens, Greece, 2007

3. Member, Scientific Committee, Developments in Infectious Diseases Annual Conference, Athens, Greece, 2007
4. Invertebrate model systems to identify novel antifungal agents, National Research Centre, Athens, Greece, 2007
5. *Cryptococcus neoformans* interactions with *C. elegans*, American Society for Microbiology 107th General Meeting, Toronto, Canada, 2007
6. Studying microbial pathogenesis using *C. elegans* Department of Microbiology, National University of Athens, Greece, 2007
7. Antifungal therapy, Infectious Disease Society of Greece educational program, Athens, Greece, 2008
8. Developments in antifungal therapy, "Agia Sophia" Children's Hospital, Athens, Greece, 2008
9. Update in fungal pathogenesis, National Research Centre, Athens, Greece, 2008
10. Infective endocarditis: The team approach, 18th WSCTS (World Society of Cardio-Thoracic Surgeons) World Congress, Kos Island, Greece, 2008
11. Risk factors for invasive aspergillosis, Hellenic Society of Medical Mycology, Thessaloniki, Greece, 2008
12. Antifungal therapy: Advances and advice from the worms, 15th International Symposium on Infections in the Immunocompromised Host, Thessaloniki, Greece, 2008
13. New treatments for Gram-positive pathogens, Henry Dunant Hospital, Athens, Greece, 2009
14. Insects as model organisms for medical research. Workshop-Insect Biotechnology, Frankfurt, Germany, 2009
15. Developments in antifungal therapy, Meet the Expert, Case presentations session, 4th Trends in Medical Mycology, Athens, Greece, 2009
16. Invertebrate model hosts, Hellenic Pasteur Institute, Athens, Greece, 2010
17. Invertebrate model hosts, Kapodistrian National University, Athens, Greece, 2010
18. Antifungal drug discovery using a *C. elegans*-based whole animal HTS. 1st International Meeting on Model Hosts, Aegean Conferences, Crete, Greece, 2010
19. Asking the worms for advice-*C. elegans*-based whole animal HTS. Institut Pasteur, Paris, France, 2011
20. Bacterial-Fungal interactions. COST Exploratory Workshop "Biofilms: Friend or Foe", Berlin, Germany, 2011
21. Fungal Diagnostics: An Overview and Novel Rapid Diagnostics. 5th International Transplant Infectious Disease Conference. Transplant Infectious Disease Society, Glasgow, UK, 2011
22. Exciting cases in Transplant Infectious Diseases. 5th International Transplant Infectious Disease Conference, Transplant Infectious Disease Society, Glasgow, UK, 2011

23. Session: Bacteria. 5th International Transplant Infectious Disease Conference, Transplant Infectious Disease Society, Glasgow, UK, 2011
24. Visiting Professorship, Oral Biopathology Program, Universidade Estadual Paulista (UNESP), S.J. dos Campos, Sao Paulo, Brazil, 2011
 - a. As part of this visit, I gave the following talks:
 - b. Asking the worms for advice
 - c. Insect and other invertebrate models
 - d. Systemic fungal infections: an overview
 - e. Whole animal high throughput screening for antimicrobial discovery
 - f. The publication process. An interactive discussion
25. Model hosts in drug development and the study of probiotic bacteria. 2nd International Conference on Model Hosts, Aegean Conference, Ixia, Rhodes, Greece, 2012
26. Visiting Professor, Southern Medical University, P.R. China, 2013
27. As part of this visit, I gave the following talks:
28. “The organization of an Infectious Diseases Division. Local, national and global roles.” Southern Medical University, Guangzhou, P.R. China
29. “Alternative model hosts for the study of infection” Southern Medical University, Guangzhou, P.R. China
30. “The *C. elegans* model for the study of host-pathogen interactions” Second Military University, Shanghai, P.R. China
31. “Invertebrate Model Hosts for the study of pathogenesis” Institute of Microbiology, Chinese Academy of Sciences, Beijing, P.R. China
32. Bacterial-fungal interactions in *C. elegans*. Bacterial-Fungal Interactions: A Federative Field for Fundamental and Applied Microbiology Conference. Roscoff, France, 2013
33. Mucormycosis around the world: Epidemiological and Clinical variations. 3rd International Forum on Zygomycosis. Marathon, Attica, Greece, 2014
34. Invertebrate whole animal models, XIVth International Congress of Mycology and Eukaryotic Microbiology, International Congress of Microbiology, Montreal, Canada, 2014.
35. A multi-host approach for the systematic analysis of virulence factors in *Cryptococcus neoformans*. 3rd International Conference on Model Hosts, Crete, Greece, 2015
36. *Caenorhabditis elegans*. 2015 annual meeting organized by the Antimicrobial Agents Section of the French Society for Microbiology, Paris, France, 2015
37. Model hosts in drug discovery. 4rd International Conference on Model Hosts, Crete, Greece, 2017

38. The greater wax moth *Galleria mellonella* in the study of microbial pathogenesis and antimicrobial drug discovery, Insecta International Symposium, Giessen, Germany, 2018 [Keynote Lecture].
39. Antimicrobial drug discovery. AMR Symposium, Utrecht, The Netherlands, 2018
40. Cross-kingdom interactions in the respiratory tract and an update on community acquired pneumonia. American Thoracic Society Assembly on Pulmonary Infections and Tuberculosis Webinar, 2018.
41. Medicine and Infectious Diseases in the era of limited resources and microbial resistance, National and Kapodistrian University of Athens, Greece, 2019.
42. Antimicrobial agents against MRSA persisters. 5th International Conference on Model Hosts. Chania, Greece, 2019
43. Therapeutic targeting of *S. aureus* persisters. IDWeek2019 annual meeting, Washington, DC, 2019

Grants

1. Title: “Opportunistic infections among patients with HIV/AIDS”.
 Dates: 1995-1997
 Role: N/A
 Sponsor: Amphiarion Foundation of Chemotherapeutic Studies, Athens, Greece
 This fellowship provide me with funding to study the impact of opportunistic fungal infections among HIV-infected individuals. This funding resulted in a series of papers detailing the dramatic morbidity and mortality associated with systemic fungal infections among patients with HIV/AIDS.
2. Title: “Study of host-pathogen interactions using *C. elegans*”
 Dates: 2000- 2003
 Role: N/A
 Sponsor: Howard Hughes Medical Institute (Postdoctoral Research Fellowship for Physicians).
 The major goal of this project was to study microbial pathogenesis using *C. elegans* and mammalian models. My work on the contribution of quorum sensing in virulence and the screen of a library of mutants for decrease in virulence resulted in a series of original papers detailing the use of this surrogate host for the study of gram-positive bacteria.
3. Title: “A *Caenorhabditis elegans* model of fungal pathogenesis”.
 Dates: 2003- 2004
 Role: N/A
 Sponsor: Infectious Disease Society of America (Fellowship in Medical Mycology)

The major goal of this project was to expand the *C. elegans* model in the study of fungal pathogenesis. My work resulted in a series of papers detailing the use of *C. elegans* and other invertebrate model hosts in the study of fungal pathogens.

4. Title: “*Caenorhabditis elegans*: a simple model host for the study of innate immunity and apoptosis”.
Dates: 2003-2004
Role: PI
Sponsor: Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital

The major goal of this project was to study evolutionarily preserved pathways associated with innate immunity. This work resulted in a paper detailing the similarities between nematode and mammalian responses to fungal infection.

5. Title: “*C. neoformans*: identification of novel virulence factors”.
Dates: 2003-2004
Role: PI

Sponsor: Harvard Medical School Center for AIDS Research

The major goal of this project was to identify novel virulence pathways associated with cryptococcal virulence. This work resulted in the identification of *ROM2*, a gene essential for mammalian infection from this important pathogen.

6. Title: “Use of the *Caenorhabditis elegans* model of fungal pathogenesis to identify virulence factors of the pathogenic yeast *Cryptococcus neoformans*”
Dates: 2003-2007

Role: PI

Sponsor: Ellison Medical Foundation (New Scholar Award in the Global Infectious Diseases)

Funding Amount: \$200,000

The major goal of this project was to study the role of *ROM2* in cell division.

7. Title: “*C. elegans* as a model system for *Cryptococcus neoformans* pathogenesis”
Dates: 2005-2008
Role: PI

Sponsor: NIH –K08 AI63084

Funding Amount: \$378,270

The major goal of this project was to develop and study libraries of *C. neoformans* mutants for novel virulence factors. This fund resulted in a series of studies on the use of *C. elegans* as a surrogate host for the study of fungal pathogenesis and the identification of antifungal compounds.

8. Title: “Characterization and predictability of fungal infections among critically ill trauma and emergency patients”.
Dates: 2008
Role: Co-PI with Dr. George Velmahos

Sponsor: Astellas Pharma
Funding Amount: \$150,000

The major goal of this project was to study and characterize systemic fungal infections among trauma and emergency patients. Two manuscripts detailing the findings from this work are currently in preparation.

9. Title: “A *C. elegans* high-throughput assay for the identification of new antifungal agents”.
Dates: 2008-2012
Role: PI
Sponsor: NIH –R01 AI075286
Funding Amount: Total direct costs over the entire funding period: \$750,000

The goal of this grant was to develop high-throughput, whole animal assays for the identification of compounds with antifungal activity.

10. Title: “Use of NMR technology in the diagnosis of candidemia”
Dates: 2011-2012
Role: PI
Sponsor: T2 Biosystems
Funding Amount: Total direct costs over the entire funding period: \$55,500

The aim of the study was the clinical evaluation of a novel, nanotechnology-based molecular assay for the diagnosis of invasive candidiasis.

11. Title: “Genome-wide investigations in fungal pathogens utilizing an invertebrate model host”.
Dates: 2009-2012
Role: PI
Sponsor: NIH –R21 AI079569
Funding Amount: Total direct costs over the entire funding period: \$250,000

The studies detailed in this proposal evaluated a large collection of random *Cryptococcus neoformans* and *Candida albicans* mutants and implement *C. elegans* assays to identify genes associated with evolutionarily preserved fungal virulence traits.

12. Title: “The role of *Candida* colonization in bacterial VAP”.
Dates: 2011-2012
Role: PI
Sponsor: Astellas Pharma
Funding Amount: Total direct costs over the entire funding period: \$102,500

The goal of this proposal was to evaluate the clinical significance of *Candida*-bacterial interactions in VAP.

13. Title: Harvard-wide Program on Antibiotic Resistance; The title of the Mylonakis subproject is: “Identification of pathways that can be targeted for the development of novel therapies for MRSA.”
Dates: 2009-2011

Role: PI of subproject, PI is M. Gilmore
Sponsor: NIH –P01 AI 083214
Funding Amount: Direct cost for subproject 4 (per year): \$260,000
(Mylonakis lab portion = 190,422 per year)

This was a multi-investigator program project grant The aim is to explore novel ways to identify antimicrobial compounds effective against methicillin resistant *S. aureus* and to study the mechanisms by which *S. aureus* acquires antibiotic resistance.

14. Title: Targeting Multidrug Efflux Systems in *Francisella tularensis* and *Burkholderia pseudomallei*.

Dates: 2012-2013

Role: PI of a Sub-contract, PI: Dr. G. Tegos

Sponsor: Threat Reduction Agency (DTRA)

Funding Amount: Mylonakis lab portion = 104,422/year

This was a multi-investigator project grant. Our sub-contact focuses on the use of invertebrate models for the study of antimicrobial compounds.

15. Title: Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT Study)

Dates: 4/26/13-6/30/14

Role: PI

Sponsor: T2 Biosystems \$200,000

The aim of the trial is to determine the feasibility of the T2 Candida Tests and the T2Dx Instrument.

16. Title: Novel Paradigms for the Treatment of Biofilm Forming Pathogens.

Sponsor : Brown Medical School Mylonakis (Co-PI)

Dates: 07/01/14-6/30/15

Role Co-PI

The goal of this study is to develop compounds with activity against bacterial biofilms.

17. Title: “The immunomodulatory properties of antifungal agents

Dates: 1/1/15-12/31/16

Role: PI

Sponsor: Astellas Pharma

Funding Amount: Total direct costs over the entire funding period: \$120,500

The goal of this proposal was to the effects of antifungal agents in mammalian immunity.

18. Title: Harvard-wide Program on Antibiotic Resistance; The title of the Mylonakis subproject is: “Identification of pathways that can be targeted for the development of novel therapies for MRSA.”

2012-2016

Role: PI of subproject, PI is Dr. M. Gilmore

Sponsor: NIH –P01 AI 083214

Funding Amount: Direct cost for subproject 4 (per year): \$285,764

(Mylonakis lab portion = 142,882 per year)

This is a multi-investigator program project grant. The aim is to explore novel ways to identify antimicrobial compounds effective against methicillin resistant *S. aureus* and to study the mechanisms by which *S. aureus* acquires antibiotic resistance.

19. Title: Identification of immune-modulatory compounds
Dates: 3/1/13-2/28/17
Role co-PI
Sponsor: Boehringer Ingelheim
Funding Amount: Total direct costs over the entire funding period: \$603,324
The effort is to evaluate libraries of chemical compounds and the identification and development of compounds that augment evolutionarily preserved immune responses.
20. Title: Serial Therapeutic and Antifungal Monitoring Protocol (STAMP Study)
Dates: 9/29/14-4/25/17
Role: PI
Sponsor: T2 Biosystems, Inc
The major goal of this project is to study the sensitivity and specificity of T2MR technology for the diagnosis of bacteremia.
21. Title: SCY-078 Phase 2 dose ranging study of SCY-078 in invasive candidiasis
Dates: 1/29/15-2/3/17 0.12 calendar
Role: PI
Sponsor: SCYNEXIS, Inc.
The major goal of this project is to study a new antifungal agent (SCY-078) for the management of candidemia.
22. Title: Metranscriptomic analysis to profile oral microbiome responses to broad-spectrum antibiotics during treatment of community-acquired pneumonia.
Dates: 4/1/15-6/30/16
Sponsor: Brown University
Role: Co-PI
The major goals of this project are to conduct a pilot feasibility study directly related to the metranscriptomic profiling of clinical and oral microbiome samples.

Current grants

23. Title: T2Bacteria Panel Pivotal Study (T2Bacteria)
Dates: 12/4/2015 – ongoing
Sponsor: T2 Biosystems, Inc
Role: PI
The major goal of this project is to evaluate T2MR technology for the diagnosis of invasive candidiasis.
24. Title: The impact of vaccine-preventable infections among residents of long-term care facilities (LTCF) a clinical study.
Dates: 9/1/2017 – 8/31/20

Sponsor: Sanofi Pasteur

Role: PI

The major goal of this project is to evaluate preventable infections in the continuum of care.

Funding Amount: Direct cost over 3 years: \$1,094,000

25. Title: Harvard-wide Program on Antibiotic Resistance; The title of the Mylonakis subproject is: "Identification of pathways that can be targeted for the development of novel therapies for MRSA."

Dates: 2016-2021

Role: PI of subproject, PI is M. Gilmore

Sponsor: NIH –P01 AI 083214

Funding Amount: Direct cost for subproject 4 (per year): \$285,764

This is a renewal of a multi-investigator program project grant. The aim is to explore novel ways to identify antimicrobial compounds effective against methicillin resistant *S. aureus* and to study the mechanisms by which *S. aureus* acquires antibiotic resistance.

26. Title: Evaluation of new antimicrobial compounds

Dates: 9/2018-7/2019

Role: PI

Sponsor: Chemic Labs

Funding Amount: \$20,000

The aim is to explore the in vitro efficacy of antimicrobial compounds.

27. Title: COBRE Center for Antimicrobial Resistance and Therapeutic Discovery

Dates: 2018-2023

Role: PI

Sponsor: NIH – P20GM121344-01A1

Funding Amount: \$2,375,762 per year

The major goal of this project is to develop new therapies for infections caused by drug resistant microbes and develop junior faculty, so they can apply for independent funding.

28. Title: Evaluation of new antimicrobial compounds

Dates: 10/01/18 - 06/30/19

Role: PI

Sponsor: Chemic Labs

The goal of the project is to evaluate new antimicrobial compounds.

Grants-pending

R01 (PI: Mylonakis)

07/01/2020 - 06/30/2025

National Institutes of Health

\$270,000 (annual)

Title: *Lactobacillus paracasei* impregnated gellan gum against oropharyngeal candidiasis

R01 (PI: Mylonakis; multi-PI grant)
National Institutes of Health

07/01/2020 - 06/30/2025
\$170,000 (annual)

Title: Defining the nasal microbiome as a determinant of aging-associated MRSA colonization

Research Funding as Sponsor of Post-doctoral Fellows or Students

Beth Fuchs	Research Fellowship from the Massachusetts General Hospital-ECOR Fund for Medical Discovery 3/1/2007-2/29/2008	Title: "Immuno-modulatory effects of caffeic acid phenethyl ester (CAPE)" The major goal of this project is to study the effects of CAPE in host immunity.
Read Pukkila-Worley	NIH- NIAID T32 AI07061-31 7/1/2008-6/30/2009	Title: "A <i>Caenorhabditis elegans</i> model of the host-pathogen interaction" The major goal of this project is to study fungal pathogenesis and the host innate immune response using a systemic fungal infection by the human pathogen <i>C. neoformans</i> in the model host <i>C. elegans</i>
Anton Peleg	Post-graduate Scholarship from the University of Queensland 1/1/2007-12/31/2009	Title: "The perils and pearls of <i>Acinetobacter</i> " The major goal of this project is to study the virulence of <i>Acinetobacter</i> spp. using <i>C. elegans</i> .
Read Pukkila-Worley	NIH Loan Repayment Program 7/1/2008-6/30/2010	Title: "A whole-animal, automated, high-throughput screen for novel antifungal compounds" The major goal of this project is to develop an automated high-throughput screen for novel antifungal compounds using a <i>C. elegans</i> system

Tianhong Dai	Bullock-Wellman Fellowship 1/1/2009-12/31/2009 The fellowship requires combined mentorship and collaboration between two HMS faculty members, at least one of whom is based at the Wellman Center. Tianhong's Wellman faculty mentor is Dr. Mike Hamblin.	Title: "Photodynamic therapy in-vivo for multi-drug resistant wound infections". The overall objective of this proposal is to explore anti-microbial photodynamic therapy (PDT) as a therapeutic option for multi-drug resistant wound infections.
Read Pukkila-Worley	Postdoctoral Fellowship in General Immunology from the Irvington Institute Fellowship Program of the Cancer Research Institute 7/1/2009-6/30/2012	Title: "A <i>C. elegans</i> and <i>C. neoformans</i> model of the host-pathogen interaction" The major goal of this project is to characterize the host-pathogen interactions between the nematode <i>C. elegans</i> and the pathogenic fungus <i>C. neoformans</i> .
Anton Peleg	Research Fellowship-The Massachusetts General Hospital ECOR Fund for Medical Discovery 7/1/2009-6/30/2010	Title: "Uncovering evolutionary defense mechanisms in prokaryote-eukaryote interactions; the potential for novel therapeutic targets". The major goal of this project is to study pathogen-pathogen interactions between pathogenic bacteria and fungi.
Read Pukkila-Worley	Research Fellowship from the Massachusetts General Hospital-ECOR Fund for Medical Discovery 7/1/2009-6/30/2010	Title: "A <i>Caenorhabditis elegans</i> and <i>Cryptococcus neoformans</i> model of the host-pathogen interaction" The major goal of this project is to characterize the <i>C. elegans</i> response to pathogenic fungi.
Jeff Coleman	NIH-T32 7/1/2010-6/30/2011	Title: "Host-pathogen studies using <i>C. elegans</i> " The major goal of this project is to study fungal virulence using <i>C. elegans</i> .

Read Pukkila-Worley NIH-K23
7/1/2010-6/30/2015

Title: “*Cryptococcus neoformans* model of the host-pathogen interaction”

The major goal of this project is to characterize the *C. elegans* response to pathogenic fungi.

Jeff Coleman NIH-T32
7/1/2013-6/30/2015

Title: “Fusarium pathogenesis”

The major goal of this project is to study the pathogenesis of *Fusarium* spp..

Daniel Kirienko NIH-T32
12/2012-12/2014

Title: “HIV and Other Infectious Consequences of Substance Abuse”

The major goal of this project is to train fellows from varied disciplines on the effects which substance abuse can have on HIV and other infectious diseases.

Tatiana Johnston NIH T32
7/2014-6/2016

Title: “HIV and Other Infectious Consequences of Substance Abuse”

The major goal of this project is to train fellows from varied disciplines on the effects which substance abuse can have on HIV and other infectious diseases.

UNIVERSITY TEACHING ROLES

Teaching of Students in Courses

- 2008 Lecture on “Infective endocarditis” to the Bulfinch Medical Group (a group of 10-15 primary care providers with approximately 10 nurses, nurse practitioners and other staff). This talk was a part of the Medical Management Conferences Clinical Updates for Primary Care (652HMS) at the Massachusetts General Hospital
- 2008 Lecture on “Cellular functions: Translation” to a group of 5 students that are interested in Microbiology. The lecture was part of the Harvard graduate course “Diverse Microbial Strategies for Metabolism, Pathogenesis, and Chemical Signaling”, Life Sciences 190r.
- 2012- 2017 Annual introductory lectures on Infectious Diseases and Immunology, Brown University.

Laboratory and Other Research Supervisory and Training Responsibilities

2007-2012 Participating Faculty, Harvard Initiative for Global Health, Summer Undergraduate Research Fellowship

HOSPITAL TEACHING ROLES

- 2004 Lecturer, *C. elegans* and other Invertebrate Model Systems to Study the Biology and Pathogenesis of Human Pathogenic Fungi, Harvard Medical School
- 2004 Lecturer, Invertebrate Model Systems to Study the Biology and Pathogenesis of Human Pathogenic Fungi, Massachusetts General Hospital
- 2004 – 2012 Infectious Diseases teaching attending, Massachusetts General Hospital supervise medical students, medical residents and infectious disease fellows on a wide variety of topics with particular focus on infections in the immunocompromised host and fungal infections.
- 2008 Lecturer, Antifungal therapy in the ICU, Surgical Intensive Care Unit and Division of Trauma, Massachusetts General Hospital
- 2008 Lecturer, *C. elegans* and the study of fungal pathogenesis, Harvard Joint Weekly Infectious Disease Conference, Massachusetts General Hospital
- 2008 Lecturer, Use of *C. elegans* to model fungal infection and to screen for new antifungal agents. 3rd Annual MGH Research Symposium at Simches Research Center
- 2008 – 2012 Medicine teaching attending, Massachusetts General Hospital Supervised medical students and residents during attending service on the Bigelow Medicine service at Massachusetts General Hospital.
- 2012 – Infectious Diseases teaching attending, RIH and TMH Supervised medical students and residents during attending service on the Infectious Diseases general and transplant services.

OTHER TEACHING ROLES

- 2000-2006 CME Editor for Infectious Diseases, eMedicine
- 2006-2013 Mentor and preceptor, Summer Research Trainee Program (SRTP), a program to “build a pipeline of minority students interested in academic biomedical research careers”. This program is organized by the MGH Multicultural Affairs Office and involves “underrepresented in medicine students who have completed at least three years of college”
- 2004-2014 Faculty at the annual Molecular Mycology course. This course takes place at the Marine Biology Laboratory, Woods Hole, MA and teaches updated techniques in Mycology in a highly selected group of 16-18 post-doctoral fellows from around the world. In addition to lecturing at this course, I teach the students on the use of invertebrate model hosts for the study of fugal host-pathogen interactions.

Importantly, through a series of hand-on experiments, the students learn how to implement these models.

Recent Trainees (last 6 years)

NAME	POSITION	DATES	CURRENT TITLE
Aguirre, Jesus	Student	5/16 – 8/16	Medical student
Alan, Seydanur	Student	8/14 – 10/14	Medical student
Alevizakos, Michail	Post-doctoral Research Assoc.	10/15 – 4/17	Fellow in Cardiology, Johns Hopkins
Andreatos, Nikolaos	Clinical Research Assist.	9/16 – 3/18	Clinical Research
Antoran, Aitziber	Research Associate	2/17 – 8/17	Research Associate
Arvanitis, Marios	Post-doctoral Fellow	11/12 – 6/14	House Officer, BMC
Balog, Steven	Student	9/14 – 5/15	N/A
Barros, Patricia	Student	9/15 – 11/15 8/19 – 12/19	Post-doctoral Fellow
Benitez, Gregorio	Student	4/19 – 6/20	Medical Student
Cole, Richard	Student	6/15 – 8/15	N/A
Coleman, Jeff	Post-doctoral Fellow	6/09 – 6/13	Assistant Professor, Auburn University
Cruz, Lana	Research Associate	3/16 – 1/17	N/A
DaSilva, Danielle	Research Associate	6/16 – 12/16	Research Associate
Detsis, Marios	Post-doctoral Fellow	10/15 – 4/16	Medical Director, Pfizer, Greece

Desalermos, A.	Post-doctoral Fellow	6/10 – 6/12	GI Fellow
Dos Santos, Jessica	Research Associate	2/17 – 4/17	Post-doctoral Fellow
Eatemadpour, Soraya	Research Associate	9/14 – 5/16	Associate Scientist, Rhode Island Hospital
Fleury, Elvira	Student	2/19 – 12/19	Medical Student
Flokas, Myrto	Post-doctoral Research Assoc.	8/15 – 4/17	Pediatric resident, NYC
Fuchs, Helen Beth	Post-doctoral Fellow	6/06 – 6/12	Assistant Professor (Research), Brown Univ.
Furtado, Thais	Student	2/16 – 4/16	PhD in Microbiology
Gallotti, Bruno	Student	6/15 – 8/15	Postdoctoral fellow
Grigoras, Christos	Senior Research Assist.	5/15 -	
Hendricks, Gabe	Research Associate	12/14 – 4/17	Patent Office, MBL
Hong, Shinyoung	Research Associate	6/18 – 9/19	Research Associate
Huang, Xiaowen	Research Associate	12/13 – 6/14 8/17 – 6/18	Assistant Professor, Southern Medical University, Guangzhou, China
Jang, Mary	Student	01/18 – 08/20	N/A
Jayamani, Elam	Research Associate	2/12 – 1/17	Research Associate
Johnson, Grace	Student	02/19 – 02/20	N/A
Junqueira, Juliana	Visiting Professor	3/16 – 8/16	Associate Professor, UNESPI, Sao Paulo, Brazil

Kahn, Amir	Research Associate	2/17 – 7/17	Research Associate
Kalligeros, Markos	Research Associate	8/18 -	Research Associate
Karanika, Styliani	Research Associate	8/13 – 4/16	Medical Resident
KC, Pooja	Research Associate	8/19 -	
Khader, Raja	Research Associate	12/17 –	Research Associate
Kim, Wooseong	Research Fellow	8/13 – 9/19	Research Fellow
Kim, Younghoon	Post-doctoral Fellow	6/09 – 1/12	Assistant Professor, Chonbuk National University, Jeonju, Republic of Korea
Kinamon, Tori	Student	6/16 – 12/17	Medical Student
Kohistani, Fariha	Student	4/19 – 5/20	Medical Student
Komura, Tomomi	Research Associate	5/13 – 3/14	Assistant Professor
Kourkoumpetis, Themis	Post-doctoral Fellow	6/10 – 6/12	GI Fellow
Koutsomitis, Dimitrios	Student	5/15 – 8/15	Bachelor of Science
Lama, Kelsang	Research Associate	2/19 – 4/19	Research Associate
Li, Dedong	Research Associate	11/12 – 11/13	Assistant Professor
Lee, Kiho	Post-doctoral Research Associate	1/13 –	Post-doctoral Research Associate
Li, Gang	Research Associate	11/13 – 10/14	Associate Professor
Li, Yan	Post-doctoral	8/13 – 8/14	Vice Director/Pharmacy
Liu, Qing Zhong	Research Associate	2/16 – 2/17	N/A
Lewis, Greyson	Student	3/13 – 8/13	Medical Student
Martins, Cleide	Research Associate	2/16 – 1/17	Research Associate

Mishra, Biswajit	Post-doctoral Research Associate	6/19 -	Post-doctoral Research Associate
Mohan, Raj	Research Fellow	9/13 – 8/15	Research Scientist
Muhammed, Maged	Research Associate	6/13 – 6/15	Hospitalist
Mylona, Evangelia	Research Associate	1/19 -	Research Associate
Nergiz, Hilal	Student	6/15 – 8/15	Medical Student
Onur, Pelin	Research Associate	12/16 – 5/2018	Research Associate
Oscar, Lewis	Post-doctoral Research Associate	3/19 -	Post-doctoral, Research Associate
Padua, Michael	Masters Student	6/16 – 8/16	Medical Student
Pan, Wen	Research Associate	8/17 –	Research Associate
Paudel, Suresh	Research Associate	6/14 – 6/16	Medical Resident
Peleg, Anton	Postdoctoral Fellow	6/09 – 6/11	Professor of Infectious Diseases and Microbiology and Director of Infectious Diseases at the Alfred Hospital and Monash University
Pliakos, Elina	Clinical Research Assist.	6/17 – 4/18	Clinical Research Assistant
Pokharel, Ashbita	Research Associate	5/19 – 9/19	Research Associate
Port, Jenna	Student	2/17 – 5/18	Medical Student
Poudel, Sanjay	Research Associate	4/18 – 7/18 8/18 – 1/19	Research Associate
Raimond, Katelyn	Student	4/19 – 5/20	Medical Student
Ribeiro, Felipe	Research Associate	7/16 -1/17	Research Associate
Ribeiro, Noelly	PhD Candidate	1/16 – 12/16	Postdoctoral

			Fellow
Rossoni, Rodnei	Post-grad Student	1/15 – 12/15 6/19 – 10/19	Graduate Student
Shehadeh, Fadi	Senior Research Assist.	5/17 –	Senior Research Assistant
Shen, Steven	Student	9/14 – 6/16	Graduate Student
Soares, Viviane	Research Associate	1/14 – 1/15	Assistant Professor
Souza, Ana Carolina	PhD Candidate	10/13 – 9/14	Postdoctoral fellow
Stiller, Tylin	Student	4/19 – 5/20	Medical Student
Tampakakis, E.	Post-doctoral Fellow	6/09 – 6/11	Instructor, Johns Hopkins School of Medicine
Tan, X.	Post-doctoral Fellow	6/10 – 6/12	Associate Professor, Southern Medical University, Guangzhou, China
Tansarli, Gianna	Clinical Research Assist.	9/17 – 9/18	Clinical Research Assistant
Tharmalingam, Nagendran	Post-doc Fellow	10/15 –	Post-doc Fellow
Tori, Katerina	Student	9/15 – 5/17	Medical Student
Travisano, Katherine	Student	2/19 – 2/21	Medical Student
Velloso, Marisol	Research Associate	3/15 – 12/16	Medical Student
Velmahos, Elpida	Student	6/16 – 12/16	Student, Columbia School of Public Health

Wang, Yan	Post-doctoral Fellow	6/10 – 6/12	Associate Professor, New Drug Research & Development Center, Second Military Medical University, Shanghai
Zacharioudakis, Ioannis	Post-doctoral Fellow	7/13 – 7/15	Medical Resident
Zervou, Fainareti	Post-doctoral Fellow	7/13 – 7/15	Medical Resident
Zheng, Zhaojun	PhD Candidate	9/15 – 12/16	PhD Candidate
Ziakas, Panayiotis	Instructor (Research)	1/13 – 12/15	Attending Physician, Athens

Thesis Advisor

NAME	DATES	TITLE OF THESIS
Castillo, Dawilmer	9/2014-6/2016	The effects of a novel immunomodulatory compound in <i>Staphylococcus aureus</i> infections
Chen, Roy	9/2015 – 6/2016	Exploring antimicrobial and immunomodulatory properties of compounds with efficacy against MRSA
Eatemadpour, Soraya	10/2014 – 5/2016	Inertial focusing in microchannels to develop lab-on-a-chip technologies for rapid and automated diagnosis of systemic fungal infections.
Escobar, Iliana	05/2018 – 09/2023	
Gordon, Shellyhan	10/2015 – 5/2017	Antifungal activity in <i>Galleria mellonella</i>
Guo, Zeyuan	09/2019 – 09/2021	
London, Rhoanna	6/2005-5/2007	Heterologous hosts and the study of cryptococcal host-pathogen interactions.

Nagarajan, Rekha	08/2019 – 08/2021	
O'Brian, Elizabeth	6/2008-5/2009	Yeast two-hybrid protein interactions with Rom2p and the cell wall integrity (CWI) pathway.
Pliakos, Elina	9/2013 – 5/2018	Identification of the virulence factors of <i>Pseudomonas aeruginosa</i> that induce behavioral avoidance in <i>Caenorhabditis elegans</i> .
Port, Jenna	12/2014 – 5/2018	Antimicrobial and synergistic properties of novel compounds against methicillin-resistant <i>Staphylococcus aureus</i> .
Shen, Steven	09/2014 – 5/2016	Assessment of animal models for the analysis of <i>Staphylococcus aureus</i> .
Silei, Li	09/2018 – 09/2020	
Stoukides, Georgianna	6/2106 – 5/2018	Studying the avoidance of <i>Caenorhabditis elegans</i> for the pathogen <i>Pseudomonas aeruginosa</i> .
Tang, Robin	6/2004-5/2005	<i>Cryptococcus neoformans</i> gene involved in mammalian pathogenesis identified by a <i>Caenorhabditis elegans</i> progeny-based approach.
Tori, Katerina	9/2015 – 5/2018	Development and identification of antimicrobial agents for the treatment of Methicillin-resistant <i>S. aureus</i> (MRSA).
Volpi, Connor	03/2017 – 05/2018	Correlation of antimicrobial prescription rate and socioeconomic status.
White, Alexis	09/2019 – 09/2021	
Zeldin, Sharon	02/2019 – 02/2021	